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ABSTRACT
Cancer Diagnostics Using Dynamic Near-Infrared Optical Imaging and Fluorescent 
Contrast Agents. (May 2004)
Mikhail Gurfinkel, B.S., University of Oklahoma
Co-Chairs of Advisory Committee: Dr. E.M. Sevick-Muraca
Dr. C. Li
A new optical imaging modality has been developed for small animal in vivo imaging of 
near-infrared fluorescence resulting from fluorescent contrast agents specifically 
targeted to molecular markers of cancer.  The imaging system is comprised of an 
intensified charge-coupled device (ICCD) for the detection of ultra-low levels of re-
emitted fluorescence following the delivery of an expanded beam of excitation light. 
The design of the ICCD detection system allows for both continuous wave (CW) and 
frequency-domain modes of operation.  Since the accurate acquisition of frequency-
domain photon migration (FDPM) data is important for tomographic imaging, the 
imaging system was also validated using experimentally obtained FDPM measurements 
of homogenous turbid media and diffusion theory to obtain estimates of the optical 
properties characteristic of the media.  The experiments demonstrated that the absorption 
and reduced scattering coefficients are determined least accurately when relative 
measurements of average light intensity relDCI  are employed either alone or in a 
combination with relative modulation amplitude data relACI  and/or relative phase shift data 
relθ .  However, when FDPM measurements of relθ  are employed either alone or in 
iv
combination with relACI  data, the absorption and reduced scattering coefficients may be 
found accurate to within 15% and 11%, respectively, of the values obtained from 
standard single-pixel measurements; a result that suggests that FDPM data obtained from 
an ICCD detection system may in fact be useful in tomographic imaging.
Furthermore, intensified-detection allows for sub-second exposure times, 
permitting the acquisition of dynamic fluorescence images immediately following 
administration of the contrast agent.  Experimental results demonstrate that when 
coupled with a suitable pharmacokinetic model describing targeted dye distribution 
throughout the body, dynamic fluorescence imaging may be used to discriminate 
spontaneous canine adenocarcinoma from normal mammary tissue.  A separate 
experiment demonstrates that pharmacokinetic analysis of dynamic fluorescence images 
enables one to estimate the rate constant governing Kaposi’s sarcoma tumor uptake of an 
αvβ3 integrin-targeted dye and integrin receptor turnover rate.  The rate constant for 
uptake was calculated to be 0.16-sec-1 while the turnover rate of the integrin receptor 
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Non-invasive imaging of the human body is of great importance in medicine and plays a 
critical role in the early detection and intervention of disease.1  A number of current 
imaging modalities such as conventional x-ray and nuclear imaging are employed for the 
diagnosis of diseases such as breast cancer, thyroid disease, and diseases of the gastro-
intestinal tract.  While these techniques vastly improve the overall odds of survival 
following diagnosis,1,2 they nonetheless suffer from a number of shortcomings.  
Techniques employing x-rays utilize ionizing radiation and nuclear techniques employ 
contrast agents that are radioactive, and thus, potentially hazardous especially for 
repeated use.  In addition they may also be expensive to implement and are generally
non-portable.  Additionally, because x-rays provide anatomical information, that is, 
images of tissue structure, and because nuclear imaging methods require high 
concentrations of contrast agents, neither method is particularly adept at providing 
functional information or information at a molecular level.
Near infrared (NIR) optical imaging, a technology emerging over the past quarter 
century, has garnered a considerable amount of interest for possible applications in 
medicine.  Among them, optical techniques may serve as diagnostic tools to identify 
malignant or precancerous lesions or to assess response to treatment; as surgical tools to 
identify sentinel lymph nodes or delineate the margins for tumor resection; and as a 
research tool to help identify possible molecular targets for highly specific delivery of 
This dissertation follows the style of Journal of Biomedical Optics.
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diagnostic and therapeutic agents.  Moreover, optical imaging methods are particularly 
appealing because they overcome the aforementioned shortcomings of conventional 
techniques, offering a potentially inexpensive, non-ionizing alternative or adjunct 
imaging technology.
An optical imaging technique of particular interest employs an intensified 
charge-coupled device (ICCD) detection system for the acquisition of ultra-low level 
light signals.  The ICCD serves as an area detector of surface reflectance and, as such, 
allows for the collection of a large amount of data from a relatively large surface area in 
a relatively short period of time.  As a result, this system lends itself to possible future 
clinical applications.  This dissertation describes the development of an ICCD detection 
system and its use in a number of subsequent animal studies aimed at evaluating the use 
of optical imaging for cancer detection.  Specifically, because most clinically relevant 
applications of optical imaging require the use of exogenous contrast agents due to a 
lack of intrinsic contrast, the experiments are designed to evaluate the efficacy of novel
targeted fluorescent contrast agents for in vivo imaging of carcinogenesis. Thus, a 
synergistic collaboration between engineers focused on instrumentation development 
and organic chemists devoted to contrast agent development must necessarily occur 
before NIR optical imaging can be established as a bona fide imaging modality for 
cancer diagnostics.  For this reason, the small-animal imaging studies described herein 
represents a collaboration with scientists at the University of Texas M.D. Anderson 
Cancer Center (MDACC) who developed the targeting fluorescence contrast agents, 
maintained the animal subjects, and produced the small animal models of carcinogenesis.
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While the work presented in this dissertation focuses on the development of an optical 
imaging instrument and pharmacokinetic models to describe contrast agent distribution 
in vivo for the purposes of evaluating novel targeting fluorescent contrast agents, it is not 
the intent of the author to comment on the chemistry and the development of these novel 
fluorescent contrast agents; that portion of the work was conducted entirely by 
collaborators at MDACC, under the direction of Dr. Chun Li.  Therefore, where 
appropriate, the reader is referred to other works detailing the chemistry and 
development of the contrast agents.  Instead, the subsequent experimental work is 
designed to validate the instrumentation, the proposed theories, and evaluate the novel 
contrast agents solely for purposes of diagnostic imaging.
The dissertation is organized as a series of sections, each section independent of 
the others.  This first section presents a brief motivation for near-infrared optical 
imaging.  Section 2 provides a background on contrast-enhanced optical imaging, 
including the current state of fluorescent contrast agents and the differing approaches 
employed to acquire fluorescence measurements.  Section 3 details the instrumentation 
employed in optical imaging and focuses specifically on the ICCD system used for the 
acquisition of pharmacokinetic and FDPM data presented in the subsequent sections.
Section 4 begins the sections describing experimental work acquired during the 
author’s tenure at the Photon Migration Laboratories at Purdue University and later 
Texas A&M University.  Section 4 summarizes the experimental work used to 
characterize the ICCD instrumentation, verifying accurate FDPM data acquisition for the 
purposes of estimating optical properties of tissue-like turbid media.  As of the time of 
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the writing of this dissertation, the body of the work presented in Section 4 has been 
submitted for publication consideration to Journal of Biomedical Optics.
Beginning with Section 5, NIR fluorescence optical imaging studies employing 
animal subjects are discussed. Because much of the clinical work, including all animal 
studies, presented in this dissertation represents a collaborative research effort, it is 
appropriate to acknowledge the work of the collaborators.  Therefore, where appropriate, 
the work of the collaborators is noted so that the author’s contribution can be kept in 
proper context.  Specifically, Section 5 presents experimental studies using a 
compartmental pharmacokinetic analysis of in vivo fluorescence data following 
intravenous administration of contrast agents to discriminate tumor from normal tissue in 
a canine model of spontaneous breast cancer. The results, which appeared in the journal 
Photochemistry and Photobiology, (vol. 72, pp. 94-102, 2000) represent the first time 
pharmacokinetics of fluorescent contrast agents have been used to discriminate diseased 
from normal tissue.
Section 6 expands upon the pharmacokinetic model developed in the analysis of 
the studies presented in Section 5.  This expanded three-compartment pharmacokinetic 
model is then used to evaluate the molecular specificity of an integrin receptor-targeted 
fluorescent contrast agent.  As of the time of the writing of this dissertation, the work 
within this section has been submitted for publication consideration in Nature 
Biotechnology.
Section 7 presents experimental work investigating fluorescence imaging of the 
epidermal growth factor receptor for diagnostic imaging of breast cancer.  The 
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experimental work within this section has appeared in part in the Proceedings of the 
SPIE (vol. 4967, pp. 108-116, 2000) and has been accepted for publication and will 
appear in the journals Cancer Research and Disease Markers in November, 2003.
Section 8 finalizes the experimental studies with some preliminary results on 
continuous wave (CW) fluorescence imaging studies of bone and prostate cancer, and 
preliminary results on FDPM imaging of breast cancer, bone, and prostate cancer, 
studies conducted in collaboration with researchers at M.D. Anderson Cancer Center.  
The final section, Section 9, concludes the dissertation with a brief summary and 
suggestions for future work in the area of in vivo fluorescence imaging.  Figure 1.1 
provides the organization of this dissertation.
The work presented in this dissertation has several significant implications.  First, 
the studies of Section 4 demonstrate that optical imaging, particularly frequency-domain 
photon migration (FDPM) imaging, may be used to accurately determine optical 
properties of tissue-like scattering media.  FDPM imaging differs from conventional CW 
imaging in that, in addition to capturing the average light intensity of the detected signal, 
it provides time-resolved measurements, or measurements that reflect the time-
dependent propagation of the detected light wave through the medium.  The added 
information provided by FDPM measurements enable the mathematical recovery of 
optical properties characteristic of the medium.  The results suggest that area 
measurements of FDPM may be used to extract optical properties of biological tissue 
which may infer anatomical and physiological status.  Second, the studies presented in 
Sections 5-7 demonstrate that optical imaging can be easily implemented in animal
6
Figure 1.1.  Organization of dissertation.
7
studies in order to elicit relevant data to evaluate a contrast agent’s efficacy in diagnostic 
imaging.  Finally, the studies of Section 6 demonstrate that the pharmacokinetic analysis 
of fluorescence data may be used to not only infer a contrast agent’s specificity for its 
intended target, but also to potentially evaluate in vivo molecular phenomena such as 
cell-surface receptor expression level and turnover rate, important factors for the design 
and development of novel targeted cancer therapeutics.
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2. BACKGROUND:  CONTRAST-ENHANCED OPTICAL IMAGING
2.1 Light-Tissue Interaction
A number of endogenous light absorbing molecules abound in biological tissue.  The 
absorbance spectra for a number of these chromophores, including oxy- and 
deoxyhemoglobin, melanin, and water, are shown in Figure 2.1.  As a result, tissue is 
dense and opaque to most forms of electromagnetic radiation.  There are, however, a 
number of notable exceptions.  Most biological tissue is transparent to x-rays and 
gamma rays, for instance, and therefore, it is readily imaged using a number of 
techniques such as conventional x-ray imaging, x-ray computed tomography (CT), 
conventional nuclear imaging, and positron-emission tomography (PET).  Regrettably, 
these methods suffer from a number of shortcomings, including the use of ionizing or 
radioactive radiation, non-portability, and expense of operation.  Fortunately, near-
infrared optical imaging is an emerging technology that overcomes these limitations.
Near-infrared optical imaging utilizes light in the 700 – 900-nm wavelength 
range to probe tissue.  Because light in this wavelength range is minimally absorbed by 
the primary endogenous chromophores3 (see Figure 2.1), it is predominantly scattered 
and may travel through several centimeters or more before it is finally re-emitted or 
extinguished by absorption.  The degree of scattering and absorption is described by the 
inverse of the mean free path before a scattering or absorption event, denoted by 'sµ  and 
aµ , respectively.  Because scattering and absorption are functions of the local
environment, and diseased tissue may reside in different biochemical environments
9
Figure 2.1.  Typical absorbance spectra of tissue.  Reproduced from Lim and 
Soter.3
resulting in different optical properties, interior maps of the optical properties 'sµ  and 
aµ  can in theory provide the size and position of heterogeneous volumes including
tumors.  Unfortunately, previous work has demonstrated that the difference in optical 
properties between normal and diseased tissues may be statistically insignificant, 
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especially at the early stages of tumor development.4 However, this potential setback 
may be overcome by use of fluorescent dyes to improve optical contrast.5,6
When fluorescent agents are used in conjunction with conventional optical 
imaging techniques, the properties of the dye can be used to help establish regions of 
diseased tissue.  If the dye is designed and formulated to exhibit molecular specificity for 
tumor associated markers or targets, fluorescence-enhanced optical imaging can be a 
very powerful diagnostic tool.  Thus, the success of an optical imaging technique for 
diagnostic imaging will ultimately require a synergistic union between organic chemistry 
and engineering for contrast agent and for instrumentation design and development, 
respectively.
2.2 Fluorescence Contrast Agents
To improve optical contrast in near-infrared optical imaging, fluorescent contrast agents 
may be employed.  Fluorescence refers to the process by which certain molecules absorb 
energy in the form of light of a particular wavelength and re-emit light of a lower energy 
and longer wavelength.  When light of a certain wavelength encounters a fluorophore (in 
this case a molecule of the dye) electrons are said to be 'excited' to a higher electronic 
level. The 'relaxation' of these electrons back to their ground state can occur non-
radiatively (without the emission of photons) or result in emissions of photons known as 
fluorescence (see Fig. 2.2).  The average length of time a fluorophore remains in the 
excited state is the lifetime, τ , and can be calculated as ( )Γ+= κτ 1  where κ and Γ
are the rates for non-radiative and the radiative relaxation.7 Furthermore, the relative 
amount of fluorophores that 'relax' back to the ground state via fluorescence is known as 
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the quantum efficiency, φ , and can be calculated as the ratio of rate constants 
( )Γ+Γ= κφ .7 The absorption properties due to the presence of fluorophore, faxµ , and 
the fluorophore lifetime, τ , may further be used to characterize the nature of tissue.
Figure 2.2.  Modified Jablonski diagram illustrating the physical processes that 
occur after a molecule absorbs a photon.  Adapted from Lakowicz7 and Harris.8
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Characteristics important to consider in optimizing imaging properties of NIR 
fluorescing dyes include the following:
[1] the fluorophore should possess an excitation/emission spectra with 
maxima in the near-infrared wavelengths (700 – 900-nm) to allow for 
minimal absorption by endogenous chromophores such as 
hemoglobin, lipids, and water;
[2] the fluorophore should possess a high quantum efficiency;
[3] the fluorophore should be chemically and optically stable; and,
[4] the conjugated fluorophore should exhibit suitable pharmacological 
properties including a high specificity for the desired target and little 
non-specific interactions.
An additional feature of fluorescence imaging that may impart contrast pertains to the 
fluorophore’s lifetime.  In general, in CW imaging techniques fluorescence emanating 
from a deeply embedded probe may be masked by background fluorescence from 
fluorophores located at or just beneath the surface.  However, the use of time-resolved 
techniques permits the resolution of deeply embedded fluorophores from those residing 
near the surface.  Typically, a lifetime on the order of nanoseconds permits the detection 
of deep tissue fluorescence using the time-resolved techniques discussed in the following 
section.9  Furthermore, if the targeted fluorophore is conjugated such that it exhibits 
lifetime sensitivity to its immediate biochemical environment, the change in lifetime can 
be monitored using a time-resolved imaging technique and can provide additional 
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contrast enhancement.  Over the last several years, NIR fluorophores with optimal 
photochemical properties have been developed.
2.2.1 Indocyanine Green and the CyDye™ Fluors
Of the NIR fluorophores currently in use as optical contrast agents, the indocyanine
green is perhaps the most popular. Indocyanine green dye (ICG) remains the best 
candidate for enhancing optical contrast due to favorable excitation and emission at 
805-nm and 835-nm [see Fig. 2.3(a)], respectively, which occur at wavelengths where 
blood and tissue are relatively transparent, its approval by the Food and Drug 
Administration (FDA) for systemic administration in humans, and its commercial 
availability.  Clinical use of ICG was approved as early as 1956 (IC-Green, Akorn, 
Inc., Buffalo Grove, IL).  The dye has maintained a remarkably good safety profile since 
its introduction into clinics.  ICG provides optimal imaging of choroidal circulation, 
making it an excellent adjunct to fluorescein angiography.  ICG has also been used 
clinically for monitoring cardiac output and for assessing hepatic function.10,11
Furthermore, ICG is highly bound to plasma protein as compared with fluorescein dye 
(98% vs. 45%) and, as a result, does not leak from vessels as readily.12  Consequently, it 
is used primarily as a blood-pool agent for NIR imaging.
In addition to its nonspecificity, ICG undergoes a well-documented aggregation 
process in aqueous media, resulting in a wavelength shift of the main absorbance peak 
and a concurrent loss of absorption and fluorescence.13  Therefore, there exists a need for 
a novel composition that improves the dye stability in solution, is simple to prepare, and 
most importantly, retains the high fluorescence yield in vivo.  Rajagopalan et al. reported 
14
Figure 2.3.  Chemical structures and excitation/emission spectra of (a) ICG and (b) 
Cy5.5.  Emission spectra for ICG and Cy5.5 were obtained at 780-nm and 660-nm 
excitation, respectively.  The table, compiled from data obtained from references 
14-16, summarizes the some of the important properties of ICG and Cy5.5.
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noncovalent interaction of an anionic polymer, sodium polyaspartate, with ICG 
produced an enhanced stability of the fluorescent dye in aqueous solution.17  When left 
in aqueous solution and kept in clear bottles under normal laboratory lighting conditions, 
ICG loses most of its fluorescence due to aggregation.  However, when mixed with 
polyaspartate ICG retains strong fluorescence even at day 24 under the same storage 
conditions.17
Others have attempted to devise analogues of ICG with improved 
physiochemical properties, and more importantly, to obtain NIR dyes with functional 
groups that can be readily used to label biomolecules such as peptides, proteins, drugs, 
and oligonucleotides.18,19
Close analogues of ICG are the CyDye™ fluors marketed by Amersham 
Biosciences (Piscataway, NJ).  Although the excitation and fluorescence emission 
spectra of these dyes are blue shifted compared to ICG (emission maxima for Cy3, Cy5, 
and Cy5.5 occur at 575-nm, 675-nm, and 700-nm, respectively) [see Fig. 2.3(b)], the 
CyDye™ fluors are well suited for conjugation to antibodies and peptides for specific 
targeting of cancer.15,20,21  The relatively broad wavelength range of fluorescence 
emission available, the relative ease with which they can be conjugated for specific 
targeting, and their commercial availability make CyDye™ fluors a popular choice for 
fluorescent labeling.16
2.2.2 Tumor Targeting Dye-Antibody Conjugates
To achieve receptor localization and specific imaging of cancer, fluorescent dyes have 
been attached to various ligands.  The benefit to such specific targeting schemes is clear–
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the high selectivity and affinity of receptor ligands result in a high signal to noise ratio 
while at the same time enabling the use of low (picomolar to nanomolar) concentrations 
of the compounds.22  Most of the published fluorescent probe studies are targeted at 
cancers (at the tumor cells, themselves, or at molecular markers of the disease) in order 
to identify malignant lesions, for defining tumor spread to adjacent tissues, and as a 
guide for optimizing treatments of solid tumors.
Targeting fluorescent dyes for surface imaging was first attempted by the direct 
conjugation of cyanine dyes to monoclonal antibodies that are directed against certain 
tumor associated antigens.21,23,24  Folli et al. showed specific tumor targeting first using 
an anti-carcinoembryonic antigen monoclonal antibody coupled with fluorescein (anti-
CEA mAb–fluorescein)23 and later using the monoclonal antibody E48 coupled to 
indopentamethinecyanin (mAb E48–indocyanin) to target squamous cell carcinomas in 
mice.24  The studies reported tumor localization by both conjugates with tumor to normal 
tissue ratios of ten and eight for the case of the mAb–fluorescein conjugate and the 
mAb–indocyanin conjugate, respectively.  Furthermore, the mAb–indocyanin conjugate 
resulted in a clearly detectable fluorescent signature due to its excitation and emission 
wavelengths at 640-nm and 667-nm, respectively, whereas the fluorescence from mAb 
E48–fluorescein was detected only after removal of the mouse skin due to fluorescein’s 
emission at lower wavelengths (~500-nm).24  These results further demonstrate that the 
efficiency of tumor immunophotodiagnosis can be improved by coupling to 
fluorochromes absorbing and emitting in the red or infrared wavelengths.
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Ballou et al. prepared fluorophore conjugates of the cyanine dyes Cy3, Cy5, and 
Cy5.5 and two well-understood tumor-targeting antibodies, namely anti-SSEA-1 which 
localizes tumors expressing the SSEA-1 antigen and antibody 9.2.27 which is directed to 
a human melanoma antigen.21  Compared to fluorescein, these dyes exhibit more 
favorable fluorescent signatures, emitting in the red wavelengths.  In their studies, mice 
were tail-vein injected with 10-100 µg of the fluorophore-antibody conjugates and 
imaged using either a cooled CCD or intensified video camera.  The resulting 
fluorescence images demonstrated that although Cy3-antibody conjugates targeted 
tumors, the Cy5 and Cy5.5 conjugates were more effective in visualizing the tumors, 
particularly in deeper tissue, again due to their fluorescence at longer wavelengths.  The 
studies also showed that the conjugate-tumor interaction was so effective that 
fluorescence was still visualized from the tumor tissue 5 days after injection.
Additionally, it is well known that the epidermal growth factor receptor (EGFR) 
is overexpressed in many types of cancer.  Soukos et al. reports the use of an anti–EGFR 
monoclonal antibody to target a diagnostic fluorescent dye, Cy5.5, and a 
photochemically active dye, chlorine6, for photodynamic therapy in the hamster cheek 
pouch carcinogenesis model.25  Using a CCD camera and simple continuous wave 
fluorescence imaging, they observed specific targeting of the antibody-Cy5.5 conjugate 
and noted that the best contrast between normal and carcinogen–treated cheek pouches 
occurred between four and eight days after injection.25  Using the antibody-chlorine6
construct, they were able to specifically target tumor cells and subsequently perform 
photodynamic therapy to reduce the size of the tumors.  The results demonstrate the 
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potential for development of immunophotodiagnosis as both a diagnostic tool and a 
method of monitoring response to photodynamic therapy.  Together, these works gave 
credence to and set the stage for the burgeoning field of molecular based optical imaging 
for disease diagnosis.
2.2.3 Tumor Targeting Dye-Peptide Conjugates
Although dye-antibody conjugates were a major breakthrough in the field of optical 
imaging, several unfavorable features were inherent in the approach.  Large 
biomolecules, such as antibodies, would often elicit an adverse immunogenic reaction.26
The long plasma half-life of the antibodies would also result in high background 
fluorescence as well as long blood clearance times.26,27  Additionally, the biomolecules 
are often preferentially taken up by the liver.28  Finally, for the detection of solid tumors 
that require the diffusion of contrast agents from the vasculature, the penetration of high 
molecular weight dye conjugates is unfavorable due to the net positive pressure within 
the tumor.29  As a result, researchers have recently devised a viable alternative to the 
dye-antibody conjugate.  In this paradigm, the fluorescent dye is attached to a small 
bioactive peptide that specifically targets overexpressed tumor receptors.
Making use of a simple continuous wave optical imaging system for in vivo
fluorescence detection in a rat model, Achilefu et al. and Bugaj et al. studied peptide 
conjugates of the dye cypate, an ICG analogue.27,28,30  They demonstrated that the cypate 
dye–octreotate peptide conjugates, designated cytate–1 and cytate–66, specifically target 
somatostatin receptor–rich tumors and specifically bind to the sst2 receptors through the
octreotate peptide.27,28,30  Furthermore, they demonstrated that the cypate dye–bombesin 
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peptide conjugates, designated cybesin–1 and cybesin–66, selectively target bombesin 
receptor–rich tumors.27,28,30  In a separate analysis, Becker et al. used an intensified CCD 
camera to perform in vivo imaging of mouse xenografts after injecting the cyanine dye–
peptide conjugate, indotricarbocyanine–octreotate.  The study yielded similar high tumor 
specificity for the dye–peptide conjugate, with a tumor fluorescence threefold higher 
than that of normal tissue up to 24 hours after injection.22
Methodologies employing protein–dye conjugates to target cell surface receptors 
have also been investigated.  Becker et al. investigated the use of macromolecules as
carriers of a fluorescent contrast agent for the optical imaging of human colon cancer 
xenografts in nude mice.31  In their study, they compared two protein–dye conjugates; 
the first consisted of an indotricarbocyanine (ITCC) derivative covalently bound to 
transferrin (Tf–ITTC); the second, ITCC bound to human serum albumin (HSA–ITTC).  
They report that both compounds induced increased fluorescence contrast of tumors in 
vivo due to the accumulation of the macromolecules in the solid tumors as a result of 
enhanced vascular permeability and ineffective lymphatic drainage of tumor interstitium.  
However, the Tf–ITTC conjugate induced a higher fluorescence contrast, perhaps due in 
part to receptor-mediated internalization of the compound in tumor cells.31
Finally, in addition to small peptides and proteins, researchers have also 
investigated the use of small molecules as delivery vehicles for fluorescent dyes.  Zaheer 
et al. report the use of a pamidronate–IRDye78 conjugate, termed Pam78, to specifically 
bind hydroxyapatite, the major mineral product of osteoblasts and calcifying vascular 
cells.32  In their study, a CCD camera was used to acquire in vivo fluorescence images 
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following the intravenous injection of Pam78 in nude mice.  In addition to demonstrating 
that the dye conjugate could be used to visualize most of the bony structures of the 
animal, they directly compared the fluorescence images with radioscintigraphy, the 
current gold standard for imaging hydroxyapatite.  The fluorescence images provided 
high sensitivity, a higher resolution, and a shorter integration time (the radioscintigraphic 
image required a 30-min integration for 0.4-mCi of 99mTc radiocolloid injected compared 
to a 500-ms exposure for a NIR fluorescence image using 2.6-nmol of Pam78).32  Their 
study further demonstrates the wide scope of applications possible with NIR 
fluorescence imaging.
2.2.4 Activatable Probes
Other methodologies for targeting fluorescent dyes to tumors have been proposed and 
investigated.  Among them are schemes involving acid and enzyme cleavable conjugates 
of dye–biomolecules.33,34  Weissleder et al. conjugated Cy5.5 onto a graft copolymer 
consisting of a poly-L-lysine backbone and methoxypolyethylene glycol side chains.33
The dye molecules were conjugated in close proximity to each other in order to quench 
fluorescence.  However, following intravenous injection into tumor-bearing nude mice, 
the fluorescent probe accumulated in the tumors due to its long circulation time and 
permeable neovasculature.  An intratumoral fluorescent signal was generated by 
lysosomal proteases that cleaved the macromolecule and released previously quenched 
fluorophore.  In vivo fluorescence imaging determined a 12-fold increase in fluorescent 
signal and allowed for the detection of submillimeter-sized tumors.33
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Matrix metalloproteinase (MMP) activity is known to play a key role in many 
diseases including cancer.  As a result, MMP inhibitors have been developed as anti-
cancer drugs.  In a recent study, Bremer et al. developed an activatable fluorescent probe 
for sensing MMP activity in vivo in tumor-bearing mice.35  The MMP sensitive probe 
consisted of quenched NIR fluorophore (Cy5.5) conjugated to a MMP peptide substrate 
and a graft copolymer of methoxy-polyethylene-glycol-derivatized poly-L-lysine.  The 
probe would fluoresce when MMP enzymes cleaved the peptide substrate and released 
previously quenched fluorophore.  The fluorescent probe was injected into mice 
exhibiting the HT1080 human fibrosarcoma tumor model due to its high MMP 
production.  Subsequent in vivo imaging resulted in a significantly higher fluorescence 
signal from HT1080-bearing mice compared with control mice with tumors devoid of 
MMP activity.35  Furthermore, Bremer et al. demonstrated that the fluorescent probe 
could be used to image MMP inhibition in vivo.35  Mice with HT1080 tumors were 
treated with prinomastat, a potent MMP inhibitor, for two days and subsequently imaged.  
The images revealed that there was significantly less MMP fluorescent signal in treated 
tumors compared to untreated tumors.35
As alluded to earlier, activatable probes that do not fully quench could be best 
imaged with time-dependent methods of NIR imaging.  Again, this is because 
background fluorescence from unquenched fluorophore can often mask the fluorescence 
signal from underlying, deeply embedded fluorophore.  Additionally, specificity of 




There are three distinct methods for monitoring the propagation of NIR light and the 
emission of generated fluorescence light in response.  These methods are continuous 
wave (CW), time-domain photon migration (TDPM), and frequency-domain photon 
migration (FDPM).  
2.3.1 Continuous-Wave Imaging
The earliest and simplest methods of measuring NIR light interaction with tissue involve 
intensity-based or CW techniques.  CW techniques generally involve measuring the 
spatial distribution of light intensity at the tissue surface resulting from illumination by a 
source of constant intensity.  CW techniques may be used to measure NIR fluorescence 
from exogenous contrast agents with a point or area light source at the excitation 
wavelength incident on the tissue surface.  The collection of the fluorescence re-emitted 
from the tissue surface occurs through a point or area detector that discriminates the re-
emitted fluorescence from the excitation light.  Because the excitation light fluence 
[which represents the amount of light in terms of its local concentration (photons/volume) 
times the speed of light (length/time), or alternatively in terms of a flux 
(photons/area/time)] exponentially attenuates as it travels from the tissue surface, the 
excitation fluence always remains greatest at the tissue surface.  Furthermore, the 
amount of generated fluorescence at any given position within the tissue is proportional 
to the product of the local fluorophore concentration and the local excitation fluence.  As 
a result, a low concentration of fluorophore at or near the tissue surface can produce the 
bulk of the detected signal emitted and collected in CW techniques.  A consequence of 
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CW methods is that the signal from a deeper embedded target containing a high 
concentration of fluorophore may be easily masked by a very low concentration of 
fluorophore at or near the tissue surface.  As discussed below, methods that measure the 
time-dependence of light propagation may escape this limitation.
2.3.2 Time-Domain Imaging
In addition to measuring the spatial distribution of light intensity, time-dependent 
measurement approaches are also capable of measuring the temporal distribution of the 
detected light.  Time-resolved techniques employ an excitation light source whose 
intensity varies with time.  Time-domain photon migration (TDPM) techniques make 
use of ultra-short (femtosecond-picosecond) light pulses and detectors which are either 
fast, time-gated, or single-photon counting devices.  A light pulse is delivered to the 
tissue, which, as a result of multiple scattering, broadens with nanosecond “time-of-
flight” and attenuates as it propagates through the tissue [see Figure 2.4(a)].  In the 
presence of an NIR excitable fluorophore, a fluorescence pulse is generated within the 
tissue that is increasingly broadened and attenuated owing to the fluorescence decay 
kinetics of the fluorophore.  Because the region of highest excitation light fluence is not 
constant and propagates away from the tissue surface with time, the spatial location of 
the generated fluorescent pulse also varies resulting in the deeper origin of fluorescent 
signals re-emitted at the tissue surface.  As a result, as long as the lifetime or the average 
time for relaxation of the fluorophore is less than or comparable to the “time-of-flight” 
associated with light propagation, the detected fluorescence may, as a function of time, 
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Figure 2.4.  Schematic representation of the time-dependent propagation of light in 
the (a) time-domain and (b) the frequency- domain.
originate from various depths within the tissue in time-dependent measurement 
methods.9
2.3.3 Frequency-Domain Imaging
An alternative time-dependent measurement methodology, which is directly related to 
TDPM through the Fourier transform, is known as frequency-domain photon migration
(FDPM).  In this approach, a light source that is sinusoidally intensity-modulated at 
radio frequencies is used to launch photons into the tissue.  Typically, modulation 
frequencies range from 30-200 MHz.  As the intensity-modulated light (also referred to 
as a “photon density wave”) propagates through the tissue, its amplitude is attenuated 
and it experiences a phase-lag relative to the incident light.  In the presence of a NIR 
fluorophore, the intensity-modulated excitation fluence results in a fluorescent “photon 
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density wave” or intensity-modulated emission fluence which is further amplitude 
attenuated and phase-delayed owing to the fluorescent decay kinetics of the dye in its 
current environment.7  The phase-lag, θ , and amplitude, ACI , of the detected fluorescent 
photon density wave, measured relative to the incident light wave using a fast detector or 
array of detectors, are pronounced owing to the fluorophore’s decay kinetics [see Figure 
2.4(b)].  As a result, fluorescence-enhanced FDPM may be used to exploit the 
fluorescent relaxation process in order to improve contrast in the phase-lag and 
amplitude attenuation of the detected signal.
Similar to TDPM, the excitation light fluence in FDPM also varies in time and 
space, and the region of highest excitation fluence is not consistently located at the tissue 
surface.  Consequently, as long as the product of the fluorophore lifetime and 
modulation frequency is less than one, the detected fluorescence may originate from 
deep within the tissue - even in the presence of background dye.36  Another important
feature of FDPM measurements concerns their inherent insensitivity to ambient light.  
Because the amplitude of the detected fluorescent signal is unaffected by non-modulated 
ambient light, FDPM enables greater sensitivity and depth of penetration than 
conventional CW techniques.6,37
In practice, FDPM consists of launching an intensity–modulated plane wave or 
spherical wave of near-infrared (NIR) light into a tissue of interest.  Since NIR light 
(700-900 nm wavelengths) can penetrate several centimeters of tissue without the 
harmful radiation effects of gamma rays, x-rays, or ultraviolet light, it is especially 
26
useful for biomedical imaging and can be used to image as deep as possibly five 
centimeters from the tissue surface.37
The NIR excitation wave propagates through the tissue and when it encounters a 
fluorescent agent, it interacts with the fluorophore generating a red–shifted emission 
wave.  As the excitation and emission waves transit through tissue, they experience an 
attenuation in amplitude as well as a phase–lag or phase delay relative to the incident 
light.  The magnitude of the attenuation and the phase delay of the propagating waves 
depends upon the spatial map of local tissue optical properties, denoted by the tissue 
absorption coefficient, mxa ,µ , and the isotropic scattering coefficient, mxs ,
'µ , at both
excitation and emission wavelengths (subscripts x and m, respectively).  The wave 
generated by the radiative relaxation of the fluorophore is dependent upon the 
fluorophore’s local concentration (represented by the absorption coefficient owing to the 
fluorophore, 
xfa
µ ) as well as the local biochemical environment.  Specifically, the local 
biochemical environment of the fluorescent dye impacts the kinetics of relaxation which 
can be described by the mean lifetime of the excited singlet state, τ , as well as its 
quantum efficiency, φ , or the proportion of the excited singlet states that relax 
radiatively to release emission light (recall Figure 2.2).  Hence, the emission wave 
detected at the tissue boundary is impacted by the integrated effects of varying optical 
properties, ( mxa ,µ , mxs ,
'µ ) as well as by the properties owing to the fluorophore and its 
kinetics (
xfa
µ , τ, φ).
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Using the measurements of amplitude demodulation and phase-shift 
characteristic of the generated fluorescence photon density wave, fluorescence FDPM 
imaging seeks to recover three–dimensional spatial maps of fluorescent properties in 
order to accomplish diagnostic imaging.38-41  Such three–dimensional maps are obtained 
using a reconstruction algorithm to essentially iteratively solve an inverse boundary–
value problem.  Because of the multiply scattering nature of tissue, the solution of the 
inverse problem is the only way to extract the size, exact location, and metabolic status 
of the disease, especially if the target is located relatively deep below the tissue 
surface.38-41  Hence, the solution of such an ill–posed inverse problem is itself a topic of 
ongoing research.
Tomographic optical imaging using fluorescence requires special contrast agents 
that exhibit either molecular specificity, lifetime sensitivity, or are activated upon 
association with the targeted disease.  Furthermore, the clinical translation of 
fluorescence-enhanced optical imaging for deep tissue imaging will only occur once 
tomography is coupled with specific fluorescence contrast agents.  Unfortunately, to date 
there exists not a single targeted fluorescence contrast agent approved by the FDA for 
routine diagnostic imaging.  Therefore, there remains an opportunity for the design and 
development of specific fluorescent contrast agents for diagnostic optical imaging.  
Small animal imaging provides a convenient platform to test the development of novel 
fluorescence contrast agents and their biological activity in vivo in model systems of 
disease.  Additionally, testing novel fluorescence contrast agents in small animals in vivo
provides the added advantage that, due to the animals’ relatively small volume, 
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tomographic reconstruction is unnecessary; as evidenced by the in vivo fluorescence 
images of mammary disease in a canine subject (Section 5) and the studies conducted on 
small animals (Sections 6-8), for malignancies located relatively shallow beneath the 
tissue surface, fluorescence images can provide two–dimensional information about the 
relative location of the malignancy without requiring the solution to the inverse problem.
Before describing the experimental work, the following section details the 
instrumentation employed in making measurements of FDPM and the imaging system 
employed in the animal in vivo fluorescence imaging studies.
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3. INSTRUMENTATION
The bulk of the experimental data presented in this dissertation was obtained using an 
intensified charge-coupled device (ICCD) imaging system developed at the Photon 
Migration Laboratories.  Therefore, it is appropriate to prelude the discussion of 
experimental results with a section devoted to a detailed description of the 
instrumentation used for the acquisition of the data presented in the following sections.  
In addition to detailing the imaging system, this section describes inherent shortcomings 
of in vivo fluorescence imaging and several experimental measures devised to minimize 
their effects.
3.1 Image Intensification
Extreme low light level conditions exist during fluorescence imaging at clinically 
relevant frame rates, i.e. sub-second exposure times.  Such low-exposure imaging 
techniques require that the optical image be amplified with low noise in order to produce 
a final image with a good signal-to-noise ratio.
One such way to accomplish this amplification is via the use of image tube 
intensifiers.  Initially developed for night vision military applications, image intensifiers 
are now finding widespread applications in scientific arenas.42,43 Image intensifier tubes 
consist of three key components: the photocathode, the microchannel plate (MCP), and 
the phosphor screen.  The basic components of an intensifier tube are shown 
schematically in Figure 3.1.
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Figure 3.1. Schematic depiction of an image tube intensifier illustrating the three 
key components: the photocathode, microchannel plate, and the phosphor screen.
Reproduced from Johnson and Owen.43
The photocathode converts the incident optical image (photons) into an 
electronic image (photoelectrons).  A high voltage power supply (Fig. 3.2) maintains the 
photocathode at a negative bias (-200 – -65V) to provide a sufficient source of electrons.  
The photocathode response to incident light is an important factor that directly impacts 
the intensifiers quantum efficiency or photoresponse.  The spectral quantum efficiency 
of the photocathode, defined as the average number of photoelectrons produced per input 
photon, is a measure of photocathode response.43  Alternatively, the photoresponse may 
be expressed as radiant sensitivity, a ratio of photocathode current per watt of incident 
illumination, as a function of wavelength.43 For the image tube intensifier employed in 
the studies presented in the following sections (model FS9910C, ITT Nightvision, 
Roanoke, VA), Figure 3.3 presents typical curves of the spectral quantum efficiency and 
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Figure 3.2.  High voltage power supply used to provide the necessary voltage 
biases to operate the image intensifier.  The electrodes G1 G2 G3, and G4 are 
maintained such that the voltage potential between the electrodes are 
V65orV200V1 −−= , depending on CW or frequency-domain operation, 
respectively, V10000V2 −= , variable voltage to control the gain, and 
V4000V3 = .  Additional instrumentation and circuitry allows either time-domain 
or frequency-domain operation.  Adapted from Johnson and Owen.43
radiant sensitivity.  Therefore, in order to optimize detector sensitivity, it is critical that 
the photocathode possesses a high photoresponse in the wavelength range of interest.
After the incident photons are converted into photoelectrons by the photocathode, 
the photoelectrons are amplified by the microchannel plate.  The MCP consists of a
network of closely packed hexagonal arrays of channel electron multipliers.42,43  As the
photoelectrons pass through the channels and strike the channel walls, more electrons are
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Figure 3.3.  Typical spectral response curves of the image tube intensifier 
employed in the studies presented within this dissertation.44
produced.  Each channel operates independently to amplify and preserve the spatial 
orientation of the electronic image.  The MCP is biased positively relative to the 
photocathode, permitting the flow of photoelectrons into the MCP.43 The degree of 
amplification is a function of the voltage differential applied across the input and output 
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electrodes of the MCP (0 – 1000V).  Image intensifier tubes capable of providing 
electron gains of 107 (e– output/ e– input) are not uncommon.43  The spacing between the 
channel amplifiers determines the limiting resolution of the image intensifier tube.  For 
the intensifier employed in the following studies, a spacing of 6-µm between channel 
centers leads to a resolution of >64 line-pairs/mm.45
Having been amplified by the MCP, the spatially-preserved electronic image is 
converted back into an optical image at the phosphor screen.43  An electrode on the 
MCP-side of the phosphor screen is used to accelerate the MCP output photoelectrons to 
high energy (~ 4000V), improving the photoconversion that occurs when the 
photoelectrons strike the phosphor screen.  The decay time, or persistence of the 
phosphor, depends on the phosphor type employed in the screen and plays an important 
role in the frequency-domain operation discussed in Section 3.3.  The intensifier 
employed in the studies presented herein incorporates a P-43 phosphor screen whose 
peak emission occurs at 550-nm and whose decay time to 1% is 3-msec.42,44
3.2 Image Acquisition
The amplified optical image produced at the phosphor screen of the image intensifier 
must be captured, digitized, and stored for further data processing and analysis.  A 
convenient method to capture the amplified phosphor image requires the use of a charge-
coupled device (CCD) camera.  CCD cameras come in a variety of designs and grades 
and may be tailored to their particular application, from astronomy to microscopy to 
medical imaging.  However, common among all the cameras is the use of a light 
sensitive silicon chip, the CCD itself, as the photodetector.  The most critical feature of 
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the CCD is its quantum efficiency, or the ability to produce electronic charge from 
incident photons.  For intensified charge-coupled device (ICCD) systems, it is desirable 
that the CCD exhibits high quantum efficiency at the peak wavelength of the phosphor 
emission of the image tube intensifier.  For the ICCD system employed in the acquisition 
of experimental data presented in the following sections, the quantum efficiency of the 
SITe scientific-grade SI-003A full-frame CCD (Scientific Imaging Technologies, Inc., 
Beaverton, OR) complements the 550-nm peak phosphor emission of the image tube 
intensifier (see Fig. 3.4 ).  Other features of CCD cameras, discussed in the following 
sections, afford a great deal of flexibility that may be exploited to tailor an imaging 
system to a particular application.
Figure 3.4.  Spectral quantum efficiency of SITe scientific-grade SI-003A full-
frame CCD used in the experiments presented in the following sections.46
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3.2.1 Lens-Coupled vs. Fiber-Optic-Coupled ICCDs
In a lens-coupled ICCD assembly the image produced on the phosphor screen of the 
intensifier is coupled, as the name implies, by a lens into the optical input of a 
conventional CCD.  This type of design, shown schematically in Figure 3.5, offers 
flexibility because the intensifier is not a permanent fixture of the ICCD and its removal 
permits the operation of the system as a traditional CCD detection system.47
Furthermore, in this type of setup, replacing the intensifier is simple and straightforward.
Alternatively, in a fiber-optic-coupled ICCD assembly, the output of the image 
intensifier is coupled directly to the CCD via a fiber-optic bundle or taper.  The taper is 
larger in area at the intensifier end and smaller at the end bound onto the CCD.  Thus, 
the fiber-optic taper is commonly referred to as a reducing taper.  To achieve a smooth 
Figure 3.5.  Schematic design of a lens-coupled ICCD assembly. Reproduced 
from Johnson and Owen.43
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transition between the intensifier’s phosphor screen and the fiber-optic taper and 
maintain high resolution, an index of refraction-matching gel is applied at the interface 
and the gap is kept as short as possible.43  In this design, the coupling between the 
intensifier and the CCD is usually permanent, as de-coupling the assembly often results 
in the fiber-optic taper delaminating the CCD chip.  The fiber-optic- coupled assembly 
has a higher light-transfer efficiency than does the lens-coupled system, but its image 
distortion and resolution performance is inferior to the lens-coupled design.43  Also the 
chance for possible adverse RF interference at the sensitive CCD by the intensifier’s 
high voltage power supply is greater than for the lens-coupled assembly.  A schematic of 
the fiber-optically- coupled ICCD is provided in Figure 3.6.
Figure 3.6.  Schematic design of a fiber-optically coupled ICCD assembly.
Reproduced from Johnson and Owen.43
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3.2.2 Full-Frame vs. Frame-Transfer CCDs
Upon striking the CCD chip, photons produce electrons via the photoelectric effect.  The 
number of electrons produced, or more correctly, the magnitude of the created charge, is 
proportional to the intensity of the detected light signal.  The way the CCD transfers and 
reads this signal charge is referred to as the architecture.  There are primarily two 
distinct CCD architectures: full-frame and frame-transfer.
Full-frame CCDs are perhaps the simplest in architecture.  In the classical full-
frame CCD format, the total area of the CCD is available for photodetection.  The CCD 
design employs a single vertical or parallel register for sensing incoming photons during 
the exposure period.  The parallel register is a large array of pixels for photon exposure, 
charge integration, and charge transport.  At the completion of the exposure, the 
accumulated charge in the parallel register is ready to be read out and converted into a 
digital signal.  First, rows of pixels are shifted vertically toward the readout or serial 
Figure 3.7.  Schematic depicting the full-frame CCD architecture.48
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register.  Once in the serial register, the charge is further shifted in the horizontal 
direction out of the serial register and into the A/D converter where the analog data is 
converted into a digital signal (Fig. 3.7).46,48  This process of parallel and serial shifts 
occurs until all the charge is read out, row by row, to form an image.  A mechanical 
shutter must be used to control the exposure and prevent light from striking the CCD 
during the read process.  Otherwise, a phenomenon known as charge smearing would 
occur resulting in blurred and distorted images.48
Unlike a full-frame CCD, a frame-transfer CCD has its parallel register divided 
into two distinct areas: the image array, where images are focused, and the storage array, 
Figure 3.8.  Schematic depicting the frame-transfer CCD architecture.
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where the integrated image is temporarily stored prior to readout (Fig. 3.8).  As a result,
only one-half of the CCD pixels are utilized for photodetection.  Typically, the image 
and storage arrays are identical in size but the storage array is covered with an additional 
opaque mask to shield the underlying pixels from light. After the image array is exposed 
to light, the accumulated charge is rapidly shifted to the storage array.  This very rapid
shift-under-the-mask operation is typically performed in less than 300 microseconds and 
allows the frame-transfer CCD to operate continuously without a mechanical shutter and 
with no observed charge smearing.48  The readout of the charge from the storage array 
then proceeds via a series of parallel and serial shifts, similar to readout in a full-frame 
CCD.  However, unlike the full-frame CCD that must wait for all charge to be readout 
prior to beginning the next exposure, the image array begins to integrate charge for the 
next image while the masked storage array is being read.  The storage array is typically 
readout in full in less than 100-msec.49 As discussed in the following section, this 
multitasking feature of the frame-transfer CCD drastically improves the frame rate.
3.2.3 Frame Rate
The frame rate or the speed at which a CCD camera acquires and reads out an image is 
an important criterion in imaging studies.  It is equivalent to the inverse of the time 
needed for the CCD to acquire and readout an image, or the sum of the frame acquisition 
time and the frame read time and is typically expressed in frames per second (fps).  In 
most cases, the frame acquisition time can be approximated as the image exposure time 
while the frame read time can be estimated as the product of the number of pixels to be 
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digitized and the serial conversion time or the time required to digitize a single pixel.50







As an example, for the SITe 1024×1024 pixel scientific-grade SI-003A full-frame CCD
(the CCD employed in the experimental studies) operating with a readout rate and 
integration time of 200-KHz and 800-msec respectively, the frame rate is approximately 
0.17 fps.46 For a frame-transfer CCD having a typical readout rate of 5-MHz,49 an image 
of the same size may be acquired at a rate of 1.4 fps, or approximately 8 times the rate of 
the full-frame CCD.  As can be seen from the example, frame-transfer CCD cameras can 
vastly improve the frame rate.  The increase in the frame rate is even greater when the 
number of pixels to be digitized is increased.  Unfortunately the increase in frame rate of 
the frame-transfer CCD often comes at the expense of dynamic range or signal-to-noise 
ratio.50
3.2.4 Dynamic Range
Dynamic range refers to the ability to quantitatively detect very dim and very bright 
parts of a single image.  The dynamic range of a CCD sensor is independent of the 
application and will indicate the bit-depth of the analog-to-digital (A/D) conversion that 





where linear full well, a specific measure of pixel well capacity, and read noise, the 
noise associated with a single readout event, are expressed in number of electrons.50
As a specific example, consider again the SITe 1024×1024 pixel scientific-grade 
SI-003A CCD, which has a full well capacity of 330,000 electrons.46  At a typical 
readout rate of 200-KHz, the read noise is 12 electrons.51 The dynamic range of this 
chip is therefore 330,000:12 or 27,500. In order to take full advantage of this dynamic 
range, the camera that incorporates the SITe SI-003A CCD utilizes a 16-bit A/D 
converter (216 or 65,536 clean shades of gray). Digitization at lower than a 16-bit depth 
would sample the signal at a level below the limit imposed by the noise. The dynamic 
range is often further optimized by thermoelectrically cooling the camera unit.  A lower 
temperature results in a lower read noise and thus, yields the largest dynamic range 
possible.  For comparison, an uncooled video camera has a much higher read noise, and 
the resulting dynamic range is usually 8 bits or lower.43
The degree of accuracy required by the system will affect the speed and cost.  In 
general, a lower read noise and a larger full well capacity yields a higher dynamic range.  
Furthermore, because lower read noise is obtained at slower readout rates, these 
combined effects contributing to a higher dynamic range favor a full-frame CCD 
architecture.  Finally, camera cost generally increases with increasing dynamic range.  
As a result, dynamic range requirements should be considered very carefully when 
selecting a CCD camera.
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3.2.5 Signal-to-Noise Ratio
Signal-to-noise ratio or SNR describes the quality of a measurement. In CCD imaging, 
SNR is computed on a per-pixel basis and refers to the relative magnitude of the signal 
compared to the uncertainty in that signal. Specifically, it is the ratio of the measured 
signal to the overall measured noise among repeated exposures at a particular pixel. 50
Because light and electrical charge are quantized, the number of photons or electrons 
that pass a point during a period of time are subject to statistical fluctuations.  In a CCD, 
because the electrons comprise the signal, they also contain the inherent natural variation 
of the incident photon flux at a given point. Additionally, inherent CCD noise sources 
create electrons that are indistinguishable from the electrons comprising the actual signal.
As a result, all noise sources need to be considered when calculating overall SNR.
The inherent time-dependent variations in the photon flux incident on the CCD 
create a fluctuation in the signal that is known as photon or shot noise.  Photons 
collected by the CCD follow a Poisson distribution.50  Thus, the shot noise, or the 
standard deviation of the signal, may be expressed as the square root of the mean signal, 
shot noise = signal I QE t= × × , (3.3)
where I is the photon flux expressed in units of photons/pixel/second, QE is the quantum 
efficiency of the CCD, and t is the integration time in seconds.
Among CCD noise sources is the readout noise created by both the CCD sensor 
and the electronics themselves. Readout noise introduces a degree of uncertainty in the 
measurement and diminishes the overall SNR. The charge output at a particular pixel in 
a CCD sensor may vary given identical charge accumulation in the well.  Readout noise 
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refers to the uncertainty introduced during the process of quantifying the electric charge 
in the pixel wells.52 Typically, the readout noise is dominated by noise that arises from 
signal amplification, although noise introduced by the A/D conversion can also be 
significant.50
The final source of CCD noise is known as dark noise.  Dark noise refers to the 
generation of electronic charge in a CCD pixel well in the absence of light.  Because 
electrons can be thermally generated in the pixel wells, dark noise is a strong function of 
temperature.  Dark noise, which also follows a statistical Poisson distribution, may be 
expressed as the square root of the number of thermally generated electrons or dark 
count within a given exposure.50 Although the dark count may be subtracted from an 
image during processing, the dark noise cannot.50  To reduce the dark noise many CCDs 
are thermoelectrically cooled.  Cooling the CCD from room temperature to -25°C can 
reduce the dark noise by more than 100 fold.50
Considering all the sources of noise, the overall SNR for a CCD camera at a 
particular pixel can be calculated from the following expression:
( ) ( ) 2d r
I QE tSNR
I QE t N t N
× ×
=
× × + × +
, (3.4)
where the quantities I, QE, and t, were previously defined, Nd is the dark count expressed 
in units of electrons/pixel/second, and Nr is the read noise in electrons.
In low-light-level imaging conditions the low signal level will yield poor SNR 
values.  Also, in these conditions the read noise typically exceeds shot noise and the 
image data is said to be read-noise limited. To improve the SNR, the integration time 
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may be increased.  Although the dark count and hence dark noise also increase with 
increasing integration time, the net effect of increasing the integration time is an increase 
in the SNR.  The integration time can be increased until shot noise exceeds both read 
noise and dark noise. At this point, the image data is said to be shot-noise limited. In 
terms of SNR, the shot-noise limit represents the optimum in camera performance.
An additional way to increase the SNR is to employ a technique known as pixel 
binning.  Binning refers to the process of combining charge from adjacent pixels in a 
CCD during readout.  Binning of 1×1 implies that the pixel charge is readout from the 
individual pixels as is.  In two-fold or 2×2 binning, the charge from four adjacent pixels 
(two pixels in each the parallel and serial directions) of the CCD array are combined to 
yield a single ‘superpixel’ that contains four times the charge of the original pixels.  In 
addition to increasing the SNR, pixel binning has the added benefit of increasing the 
frame rate.  For example, two-fold binning approximately quadruples the frame rate.  
Figure 3.9.  Schematic depicting the process of pixel binning.  Pixel binning 
improves SNR and readout rate but results in diminished spatial resolution.
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Finally, although the shot-noise limit may be reached more quickly by binning 
neighboring pixels, it comes at the expense of spatial resolution.  Because spatial 
resolution is proportional to pixel size, an additional consequence of pixel binning is 
diminished spatial resolution: 2×2 binning reduces the spatial resolution by half, 4×4 
binning reduces the resolution by a factor of four, etc.  Figure 3.9 graphically illustrates 
the effect of pixel binning.
3.3 Instrument Specifications
Sinusoidal intensity–modulated excitation light is provided by a laser diode (660-nm, 
35-mW, model HL6501MG, or 785 -nm, 80-mW, model DL7140-201, ThorLabs, Inc., 
Newton, NJ).  For fluorescence-enhanced imaging an appropriate wavelength is selected 
to elicit fluorescence from an embedded fluorophore.  A laser diode driver and 
temperature controller (ThorLabs, Inc., models LDC500 and TEC2000, respectively, 
Newton, NJ) maintain a constant dc bias and wavelength, while a frequency synthesizer 
(Marconi Instruments, model 2022D, United Kingdom) superimposes a 13–dBm, 100–
MHz sinusoidal signal on the dc current.  A Nikon 50-105 mm f/1.8 zoom AF Nikkor 
camera lens and appropriate optical filters combine to focus diffuse light of the desired 
wavelength onto the photocathode of the gain-modulated image intensifier (ITT Night 
Vision, model FS9910C, Roanoke, VA).  For fluorescence-enhanced imaging the optical 
filters consist of a holographic notch-plus band rejection filter (660-nm or 785-nm center 
wavelength, Kaiser Optical Systems, Inc., Ann Arbor, MI) and a bandpass or 
interference filter (710-nm center wavelength, model F10-710.0-4-2.00 or 830-nm center 
wavelength, model F10-830.0-4-2.00, CVI Laser Corporation, Albuquerque, NM) to 
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reject backscattered excitation light and isolate fluorescence light.  Figures 3.10 and 3.11 
provide the transmission spectra of the holographic and bandpass filters used in the 
studies.  A second frequency synthesizer (Programmed Test Sources, Inc., model 
310M201GYX-53, Littleton, MA) and power amplifier (ENI, model 604L–01, 
Rochester, NY) provide the modulation to the dc current supplying the photocathode of 
Figure 3.10.  Transmission spectra of (a) 660-nm central wavelength and (b) 
785-nm central wavelength holographic band rejection filters.53,54
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Figure 3.11.  Typical transmission curve of the 710-nm center wavelength and 
830-nm center wavelength bandpass filters, where the center wavelength is 
denoted by λo and HBW is the half band-width, or the bandwidth at 50% of the 
peak transmission.55
the image intensifier (provided by GBS Micro Power Supply, model PS20060500) at 
100–MHz via a bias–T modulation circuit described in the following section.  Finally, a 
Nikon 105 mm f/2.8D AF Micro-Nikkor camera lens transmits the amplified area light 
image onto the 1024 × 1024 CCD detector array of the 16-bit CCD camera 
(Photometrics, model CH350, Tucson, AZ).  The CCD unit is thermoelectrically cooled 
to minimize the detection of any inherent dark current.
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The synchronous control of all instrumentation and data acquisition is 
accomplished using via an IEEE–488 GPIB instrument control bus and V++ software 
(Digital Optics, New Zealand).  Subsequent analysis of frequency-domain data is 
performed using Matlab software (The Mathworks, Inc., Natick, MA).
3.4 Homodyned ICCD Frequency-Domain Operation
To operate in the frequency-domain, both the excitation light source and the detector 
must be modulated at radio-frequencies, typically on the order of 100-MHz.  When the 
light detector consists of an intensified charge-coupled device (ICCD) camera, the 
modulation typically occurs at the image tube intensifier,56-60 although systems that 
utilize on-off modulation of the CCD itself are also available.61 As described herein, 
superimposing an RF frequency onto the dc bias of the photocathode of the tube 
intensifier provides a convenient method to achieve frequency-domain operation of the 
detector.
Modulation of the image tube intensifier is accomplished via a bias-T modulation 
circuit, similar to the one depicted in Figure 3.12, that superimposes an RF signal, 
typically 100-MHz, on the dc bias of the photocathode. Two resistors, denoted R1 and 
R2, and two capacitors, denoted C1 and C2, make up the key components of the bias-T 
modulation circuit.  The first resistor, R1, provides the circuit load to ensure that there 
are no circuit-loading effects by the modulation circuit on the ac signal source.62 For 
radiofrequencies a 50-Ω load is typical.62  The second passive component, the capacitor 
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Figure 3.12.  Schematic diagram of the bias-T modulation circuit used to provide 
RF modulation to the photocathode of the image tube intensifier.  R1 and R2 denote 
resistors while C1 and C2 denote capacitors.
C1, acts as a dc blocking capacitor to prevent superfluous dc signal from reaching the 
photocathode.  For the modulation circuit designed and constructed for use in the ICCD 
imager employed for the studies described within this dissertation, C1 has a value of 
11.5-nF.  The final two components R2 and C2 act together to form a low-pass filter and 
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prevent the ac signal from reaching the intensifier’s power supply.  The cutoff frequency 







where the frequency is expressed in units of Hz when the resistance R is expressed in 
Ohms and the capacitance C is expressed in Farads.  The cutoff frequency is the 
frequency above which the output voltage falls below -3dB (70.8%) of the input voltage.
Given values of 2 10 kR = Ω  and 2 11.5 nFC = , representative of the bias-T modulation 
circuit employed in the instrumental design, the cutoff frequency is equivalent to 
cutoff 1.4 kHzf = .  Thus, this low-pass filter effectively directs the 100-MHz ac signal 
towards the intensifier’s photocathode by preventing it from reaching the power supply.
In the technique of homodyne frequency mixing, the intensity of the excitation 
light source is modulated at the same frequency as the photodetector.  The excitation 
light source intensity, typically provided by a laser diode, is similarly modulated via a 
bias-T circuit.  Mathematically, the process of homodyne frequency mixing may be 
explained as the product of two signals – the detected modulated signal received by the 
image intensifier and the signal modulating the image intensifier, denoted by L and G
respectively.  The signals L and G may be represented as:59
( )cosDC ACL L L tω θ= + + , (3.6)
( )cosDC ACG G G tω η= + + , (3.7)
where the subscripts DC and AC denote the dc and ac components of the signals, 
respectively, t is time, ω is the angular modulation frequency, θ is the phase difference 
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between the incident excitation wave and the detected wave, and η represents the phase 
delay imposed by the instruments, that is, η represents the native difference in phase 
between the signals modulating the laser diode and the image intensifier.  Thus, the 
frequency mixed signal, denoted S, is simply the product of L  and G.59
( ) ( )
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Because the phosphor decay time of the intensifier is on the order of msec and 
photodetection occurs on the order of µsec (100-Mhz modulation frequency), the image 
intensifier inherently acts as a low-pass filter.59  As a result, the signal observed at the 
image intensifier is a steady state signal, denoted Sobs, and only contains the dc and low 








= + . (3.9)
Determination of the frequency-domain properties characteristic of the propagation of 
the detected light wave, namely phase shift, θ, and the modulation amplitude, denoted 
IAC, is accomplished at each pixel in the multi–pixel detection array.  The process 
involves stepping the phase of the image intensifier relative to the laser diode, η, at 
regular intervals through a complete 2π cycle.60,63,64  During each phase delay, ηd , the 
CCD camera acquires an image which is stored as an intensity array.  Following 
completion of the 2π cycle, a Fast Fourier transform (FFT) of the phase-sensitive 
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intensity data yields the phase shift, θij , and modulation amplitude, IACij at each pixel 
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where Im[I(fmax)ij] and Re[I(fmax)ij] represent the imaginary and real components of the 
digital frequency spectrum maximum, respectively, at each pixel, and N is the total 
number of phase delays.
3.5 Limitations to in Vivo Fluorescence Imaging
Despite the efforts to isolate and detect only the re-emitted fluorescent light, the major 
limitation to the detection of ultra low concentrations of fluorophore, and hence, ultra-
low levels of fluorescent light remains the inability to completely eliminate extraneous 
sources of light, primarily back-reflected excitation light.  Although the holographic 
notch-plus band rejection filter and narrow-band interference filter combine to provide 
greater than six orders of magnitude rejection of excitation light, the intensity of the 
remaining transmitted back-reflected excitation light is on the same order as the 
fluorescence intensity from nanomolar concentrations of fluorophore located at a depth 
of 4-cm within a scattering media.37  Thus, the current state of optics imposes the limit to 
deep-tissue fluorescence imaging to nanomolar concentrations of fluorophore.37
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In addition to the noise imparted by back-reflected excitation light, there exists a 
number of discrete noise sources that may corrupt images by reducing the SNR , 
especially when operating in the frequency-domain. Because frequency-domain photon 
migration imaging utilizes RF-modulated electronics, FDPM imaging is susceptible to 
electronic or RF interference.  RF interference can result from proximity to electrical 
wires and instruments, termed RF leakage.  Because electronic noise sources abound, 
especially in experimental laboratories and clinics, RF interference may result in less 
than ideal performance.  Great care must be taken to properly shield all sensitive 
components and electronics.
Finally, another obstacle in fluorescence-enhanced imaging is the inherent non-
uniformity of excitation light field.  The excitation light source, provided by a laser 
diode, is expanded via a plano-convex lens to provide a larger field of view for imaging.  
However, even with the most advanced lens optics available, a completely uniform 
expanded excitation source is unachievable.  Furthermore, because the re-emitted 
fluorescence intensity is proportional to the product of the fluorophore concentration and 
the local excitation light fluence, a non-uniform excitation light field may lead to 
erroneous conclusions.  For example, the underlying assumption in fluorescence imaging 
in vivo is that the highest fluorescence intensity signal arises from the area where the 
local concentration of fluorophore is the greatest.  While this holds true when the 
excitation light fluence is uniformly distributed, as is often the case, the excitation light 
fluence distribution is far from ideal.  Thus, the resulting fluorescence images, rather 
than reflecting the local fluorophore concentration, may instead echo the local excitation 
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light fluence.  As a result, great effort must be made to provide an excitation light field 
that is as close to uniform as possible.  
One such way to accomplish that task is via the use of holographic diffuser in 
combination with the plano-convex light expanding lens.  The end result is a more 
diffuse and hence, more uniform, excitation light field.  Figure 3.13 illustrates the effect
of the holographic diffuser.  Figures 3.13(a) and 3.13(b) are images obtained of the
Figure 3.13.  Images obtained of the expanded excitation light fluence (a) without 
and (b) with the use of a holographic diffuser.  The images in panels (c) and (d) are 
the enlarged regions highlighted by the white boxes in panels (a) and (b), 
respectively.
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expanded excitation light field using the instrumentation described in the previous 
section with and without the use of a holographic diffuser, respectively.  Figures 
3.13(c)and 3.13(d) are enlarged views of the regions outlined by the white boxes in 
Figures 3.13(a) and 3.13(b), respectively.  From the figures, the effect of the diffuser is 
evident.  With the presence of the holographic diffuser, the excitation light field is 
clearly more uniform.
Unfortunately, the added uniformity provided by the holographic diffuser comes 
at the expense of decreased excitation light intensity and, for frequency-domain studies, 
decreased modulation depth.  Figure 3.14 shows the intensity profile along a horizontal 
Figure 3.14.  Intensity profile along a horizontal slice through the images in 
Figures 3.13(a) and 3.13(b).  While the intensity is more uniform with the 
holographic diffuser present, the intensity is reduced by nearly 40%.
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slice through the images in Figures 3.13(a) and 3.13(b) (denoted by the white horizontal 
line).  From the intensity profile, although the improvement in uniformity is again quite 
noticeable; the signal intensity is reduced by approximately 40% by the addition of the 
holographic diffuser.  Finally, the holographic diffuser decreases the modulation of the 
excitation light source such that the time-variant sinusoidal nature of the light wave is 
essentially eliminated.  A frequency-domain study was conducted with and without the 
diffuser present.  Four phase-sensitive images of the expanded excitation source were 
obtained at each of 16 equally spaced phase delays between the oscillators modulating 
the laser source and detector.  An FFT of the phase-sensitive images yielded 
measurements of average light intensity (DC) and modulation amplitude (AC) over a 
region of interest overlying the expanded source light.  The addition of the holographic 
diffuser resulted in a decrease of the modulation amplitude, defined as the dimensionless 
ratio of AC/DC, of approximately 83% (from 15.3 to 2.6).  As a result, the use of a 
holographic diffuser to achieve a uniform excitation light source is inappropriate for 
frequency-domain studies.  To obtain a near-uniform excitation light field and yet 
maintain adequate modulation depth, the area of the expanded light source must be 
decreased.  While this may be adequate for the preliminary in vivo frequency-domain 
studies presented in Section 8, the limitation imposed by the non-uniformity of the 
excitation light is a topic which requires further inquiry before the imaging system 
operates optimally.
This section concludes the discussion on background and instrumentation.  The 
necessary first step following the design and assembly of the ICCD instrumentation 
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described in detail within this section was to validate the accuracy of experimentally 
obtained measurements of frequency-domain photon migration. The following section
describes experimental work designed to test and validate the instrumentation by using 
measurements of FDPM to characterize the optical properties of turbid, tissue-like media.
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4. DETERMINATION OF OPTICAL PROPERTIES OF SEMI-INFINITE TURBID 
MEDIA USING AREA MEASUREMENTS OF FREQUENCY-DOMAIN 
PHOTON MIGRATION OBTAINED WITH AN ICCD DETECTION SYSTEM
The following section describes experimental work initially intended to test and validate 
frequency-domain measurements obtained by an intensified charge-coupled device 
(ICCD) homodyne detection system.  The measurements, obtained from the surface of 
turbid, tissue-like media, were used in conjunction with a diffusion theory of light 
transport to obtain estimates of the optical properties characteristic of the media.  The 
work, which represents the first time area measurements of frequency-domain photon 
migration have been utilized to characterize optical properties of scattering media, is 
pending publication in Journal of Biomedical Optics.
4.1 Introduction
With recent advances in optics and medicine it is becoming increasingly more important 
to acquire rapid and accurate measurements of light propagation from the tissue surface 
and, using those measurements, infer the physiology of the underlying tissue.  Successful 
near-infrared (NIR) optical imaging necessitates the accurate collection of diffusely 
propagated light at the tissue surface as well as an optimization approach to recover or 
map the optical properties of the underlying tissue volume.
The study of light propagation through turbid media can broadly be divided into 
one of two classes: steady-state or continuous wave (CW) techniques, and time-resolved 
approaches, either in the time-domain (time-domain photon migration, TDPM) or in the 
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frequency-domain (frequency domain photon migration, FDPM).  Steady-state 
techniques employ a light source whose intensity is constant in time.  In these techniques, 
the spatially resolved diffuse reflectance may be used with the steady-state diffusion 
equation to obtain estimates of the optical properties.65-68  On the other hand, time-
resolved techniques, as the name implies, measure the optical response of a system to a 
light source whose intensity varies in time.  Time-domain techniques employ ultra-fast 
light pulses (on the order of femto- to picosecond) to irradiate the medium under 
investigation and photon counting or gated detectors to capture the broadened and 
attenuated pulse some distance away from the source.  The measured pulse shape may 
then be fitted to a theoretical expression to obtain the absorption and scattering 
coefficients.68,69  In frequency-domain approaches, the light source intensity is 
modulated at high frequencies (on the order of MHz) and a phase-sensitive detector is 
used to measure the amplitude attenuated, phase-shifted light signal.  The characteristics 
of the detected light wave may then be used to determine the absorption and scattering 
coefficients of the medium.70- 79
In many cases, the measurements used to determine the optical properties of 
turbid media are obtained using an infinite media geometry in which the source light and 
detected light, delivered and captured via fiber optics, are located deep within the 
media.70-75,79  Certainly the determination of optical properties has applications outside 
medical imaging for which the infinite geometry is well suited.  However, for 
applications in medical imaging, the infinite media geometry is hardly applicable.  Thus, 
the determination of optical properties requires a more relevant half-space or semi-
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infinite geometry.68,69,75-79  Furthermore, the measurements must be rapid to ensure that 
data collection concludes within a clinically acceptable time frame.  To this end an 
intensified charge-coupled device (ICCD) imaging system has been developed, capable 
of operation in the frequency domain, and capable of acquiring rapid area measurements 
of photon migration.57,59,60  Herein, the said system is used to obtain estimates of the 
optical properties of homogenous turbid media.  The results, which compare favorably to 
estimates obtained via a well-characterized single-pixel FDPM technique, further 
validate the ICCD detection system and its capacity to obtain frequency-domain data.  
To the author’s knowledge, this study presents the first time frequency-domain 
measurements obtained using an area detector of the form of an ICCD camera system 
have been employed to determine the absorption and reduced scattering coefficients of 
turbid media.
In the following sections, diffusion theory of light propagation in turbid media is 
first reviewed to establish the theoretical framework.  Next, the experimental method 
including the instrumentation used for the acquisition of area frequency-domain data and 
the scattering media investigated is described and the data analysis procedure is detailed.  
Finally, the experimental results are presented and compared with the results obtained 
from a well-characterized single-pixel frequency-domain system to demonstrate the 
validity of the technique.
4.2 Theory
The propagation of near-infrared light through biological tissue and other scattering 
media can be described by the radiative transport equation (RTE).  Given conditions of 
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high scattering and sufficient source-detector separation,80 a diffusion approximation, 
described in detail in Appendix A, may be applied to the RTE to yield a mathematical 
formulation more conducive to the study of light transport in turbid media.  Thus, 
diffusion theory is often used to describe the time-dependent photon passage through 
turbid or highly scattering media and often finds applicability in studies of time-domain 
photon migration, where source light is launched as ultra-short pulses and photon 
detection is achieved as a function of time and position.  Additionally, for studies of 
frequency-domain photon migration, where the incident source light intensity is 
sinusoidally modulated, an adequate description of photon migration is provided by the 
diffusion equation:
( ) ( ) ( ) ( )ωωµωωω ,,,, 2 rrrr SD
c
i
a =Φ+Φ∇−Φ . (4.1)
Here, i is the principal square root of -1, c is the speed of light in the medium, ( )ω,rΦ  is 
the AC photon fluence rate at position r and angular modulation frequency ω, ( )ω,rS  is 
the isotropic photon source density, and D is the diffusion coefficient defined by:










where µs and µa are the inverses of the mean free paths for scattering and absorption and 
are known as the scattering and absorption coefficients, respectively, 'sµ  is known as the 
isotropic scattering coefficient and g is the mean cosine of the scattering angle.
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4.2.1 Analytical Solutions to the Diffusion Equation
For infinite and semi-infinite media geometries, the diffusion equation may be solved 
analytically to obtain an expression for the photon fluence rate.  Herein, the method of 
Haskell et al. is followed and the extrapolated boundary condition is applied to solve for
the AC photon fluence rate at the surface.79  This boundary condition states that the 
photon fluence rate goes to zero at some fictitious boundary located a distance ls above 












where Reff is the effective reflection coefficient and represents the fraction of photons 
that is internally reflected at the boundary.  Reff is a function of the refractive indices (ni) 
of the turbid media and surroundings and has a value of 0.431 for a refractive index 
mismatch typical of that of a water-air interface ( 3.1=airwater nn 3).  The expression for 







































































where S is a complex number representative of the source AC strength (SAC) and phase 
(θs), such that,
( )sAC iSS θexp= , (4.5)
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and r1 and r2 are the distances from the point of interest to the true source located just 
beneath the surface and to the image source introduced to satisfy the boundary condition, 
respectively, and ρ is equivalent to the projection of r1 and r2 onto the surface, such that 
(see Fig. 4.1),
( )[ ] 21221 3r ρ+= D , (4.6)
( )[ ] 21222 23r ρ++= slD . (4.7)
Figure 4.1.  Schematic depicting the semi-infinite model.  The true source is 
located a distance of one mean-free path length (3D) below the surface of the 
medium, while the image source is located a distance of 2ls + 3D above the surface 
to create a net-zero fluence at the extrapolated boundary located a distance of ls
above the surface.  The true source and image source are located a distance of r1
and r2, respectively, from the detector, and ρ is the projection of r1 and r2 onto the 
surface.
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A case of particular importance and pertinent to this report involves a reflectance 
geometry detection scheme, where the source and detected light are located on the same 
surface.  In this case, the detected signal or the diffuse reflectance, denoted by R, is that 
portion of the diffuse light that is transmitted through the surface and captured by the 
detector.  It can be shown that the diffuse reflectance is proportional to the photon 
fluence rate at the surface:79
( ) ( )ωρωρ ,, Φ= AR , (4.8)
where A is a proportionality constant equivalent to:


















Here, αo is equal to one-half of the detector acceptance angle and RFresnel, the Fresnel 
reflection coefficient, is a function of the refractive indices of the turbid media and 
surroundings.  For a system with a refractive index mismatch of 1.33, and a detector 
with a large acceptance angle (such as a camera), A has a value of 0.199.  Thus, when Eq.
(4.4) and Eq. (4.9) are applied to Eq. (4.8) one obtains an analytical expression for the 





















































































Several approaches may be applied to determine the optical parameters of a 
semi-infinite media given frequency domain measurements.  In one such approach, ρ is 
fixed and measurements are obtained as a function of ω.  Alternatively, measurements 
may be obtained for a fixed ω as a function of ρ.  Finally, a technique that utilizes both a 
fixed modulation frequency and a fixed separation distance sequentially may be applied.  
An algorithm based on the measurement approach applied and the analytical solution to 
the diffusion approximation may then be used to regress the unknown optical properties.  
The imaging system described herein is capable of obtaining data at a number of 
modulation frequencies.  However, its capacity to obtain measurements simultaneously 
from an area of the medium surface makes it convenient to obtain frequency domain 
data for multiple values of ρ simultaneously at a fixed frequency.  Thus, herein the 
attention is focused on a frequency-domain method that employs a fixed modulation 
frequency and measurements obtained at a number of distances from the source to 
determine unknown optical parameters of scattering media.
4.2.2 Absolute versus Relative Measurements
In the frequency domain, the measured quantities are the steady-state reflectance or DC 
amplitude, denoted by DCI , the modulation or AC amplitude, denoted ACI , and the phase 
angle between the source and detector, θ .  These quantities are related to the diffuse 
reflectance by the following expression:
( ) ( ) ( )[ ]ωρθωρωρ ,exp,, iIR AC= , (4.11)
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where IAC(ρ,ω), is the modulus of the diffuse reflectance, and θ(ρ,ω), is the argument of 
the diffuse reflectance.  Consequently, the steady-state reflectance, modulation 
amplitude, and the phase angle are found via the following relationships:
( ) ( )0, == ωρρ RI DC (4.12)
( ) ( ) ( )[ ] ( )[ ]{ } 2122 ,,,, ωρωρωρωρ RREALRIMAGRI AC +== (4.13)













where ( )[ ]ωρ ,RIMAG  and ( )[ ]ωρ,RREAL  refer to the imaginary and real components 
of the diffuse reflectance, respectively, and ( )ωρ ,R  is the diffuse reflectance defined by 
Eq. (4.10).  Thus, given the distance from the source, angular modulation frequency, and 
optical properties of the medium, Eqs. (4.12 – 4.14), when applied to the analytical 
expression for the diffuse reflectance, may be used to obtain theoretical or predicted 
values of steady-state reflectance, modulation amplitude, and phase angle.
Moreover, frequency-domain measurements may be absolute or relative.  If 
absolute measurements are to be used, the proportionality constant A needs to be 
determined.  An additional calibration experiment must also be performed in order to 
characterize the source AC strength and phase since the quantity S appears in the 
analytical solution for the photon fluence rate.  On the other hand, since the diffuse 
reflectance is a linear function in both the quantities A and S, dividing the diffuse 
reflectance obtained at one position by a measurement obtained at a second reference 
position cancels both quantities and obviates the need to calculate the proportionality 
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constant and characterize the source.  Hence, relative FDPM measurements may be 
calculated using the relationships:
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    −
    
, (4.17)
where the superscript rel denotes relative measurements, ρref represents the distance 
from the source at some reference position, and ( )ωρ ,R  is the diffuse reflectance 
defined by Eq. (4.10).
A second, perhaps greater advantage to using relative data for the determination 
of optical properties involves the uniqueness of the derived optical parameters.  Kienle 
and Patterson previously demonstrated that the determination of optical properties is not 
unique if absolute measurements of steady-state reflectance are used.78  Figure 4.2(a) 
presents a contour plot of the steady-state diffuse reflectance typical of measurements 
obtained from an air-water interface using a detector with a large numerical aperture, (i.e. 
nwater/nair=1.33, Reff = 0.431, A = 0.199), obtained using Eq. (4.12), versus the absorption 
and reduced scattering coefficients for ρ = 0.5 cm.  The value S, representative of the 
source was further assumed to equal unity.  From the plot it is evident that for certain
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Figure 4.2.  Contour plots of (a) steady-state diffuse reflectance (cm-2), (b) AC 
amplitude (cm-2), and (c) phase angle (radians).  Values were obtained using Eqs. 
(4.12), (4.13), (4.14) and (4.10) with ρ = 0.5-cm and ω = 2π×(100-MHz).  A 
source strength of unity was assumed (S = 1).
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fixed values of the absorption coefficient, two separate values of the reduced scattering 
coefficient will yield the same steady-state diffuse reflectance.
Similarly, Figures 4.2(b) and 4.2(c) demonstrate that for certain values of the 
absorption coefficient, multiple values of the reduced scattering coefficient can produce 
the same value of the AC amplitude and phase angle [computed using Eqs. (4.13 – 4.14), 
with ω = 2π×(100-MHz)].  As a result, the determined optical properties will be non-
unique if absolute measurements of steady-state reflectance, AC amplitude, or phase 
angle are used alone or if a combination of absolute measurements are employed (i.e. 
superimposing Figures 4.2(a), 4.2(b), and 4.2(c) still results in multiple pairs of 
absorption and scattering coefficients that yield the same results).
On the other hand, the use of relative measurements leads to the determination of 
a unique set of optical parameters.  Figures 4.3(a), 4.3(b), and 4.3(c) display contour 
plots of normalized steady-state reflectance, normalized AC amplitude, and referenced 
phase angle, respectively, versus the absorption and reduced scattering coefficients.  The 
values were calculated using Eqs. (4.15 – 4.17) for ρ = 1.0 cm and normalized or 
referenced to those obtained at a distance of ρref = 0.5 cm.  As in Figure 4.2, the effective 
reflection coefficient was assigned a value of Reff = 0.431 and the angular modulation 
frequency was set to ω = 2π×(100-MHz) but no assumption about the source was 
necessary and the proportionality constant A was not required in the calculation.  The 
plots in Figure 4.3 demonstrate that for any fixed value of the absorption coefficient, 
there exists only one value of the reduced scattering coefficient that will yield a given 
value of normalized steady-state reflectance, normalized AC amplitude, or referenced
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Figure 4.3.  Contour plots of (a) normalized steady-state diffuse reflectance (a.u.), 
(b) normalized AC amplitude (a.u.), and (c) referenced phase angle (radians).  
Values were obtained using Eqs. (4.15), (4.16), (4.17) and (4.10) with ρ = 1.0-cm, 
ρref = 0.5-cm., and ω = 2π×(100-MHz).
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phase angle.  As a result, relative measurements of steady-state reflectance, AC
amplitude, or phase angle may be used alone or in combination to determine a unique 
pair of optical properties.
The following section describes the instrumentation, experimental setup, and 
experimental method employed for data acquisition as well as details the data analysis 
procedure used to obtain the final estimates of the optical properties of the turbid media 
investigated.
4.3 Materials and Methods
4.3.1 Instrumentation
The frequency domain imaging system is described in detail in Section 3.  Hence, only 
the salient features are described.  Modulated light of 785-nm provided by a laser diode 
(ThorLabs, Inc., model DL7140-201, Newton, NJ) was launched onto the surface of the 
medium under investigation via a 1000-µm optical fiber.  The fiber was positioned 
perpendicularly such that the tip just touched the medium surface.  A laser diode driver 
(ThorLabs, model LDC500, Newton, NJ) provided the diode with 50-mA of dc current 
while a temperature controller (ThorLabs, model TEC2000, Newton, NJ) helped 
maintain a constant lasing wavelength.  A 100-MHz ac signal of +13-dBm RF power, 
provided by a frequency synthesizer (Marconi Instruments, model 2022D, United 
Kingdom), was superimposed onto the constant dc bias of the laser diode.  Consequently, 
the diode delivered approximately 48-mW of optical power to the source fiber.
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A 16-bit CCD camera (Photometrics, model CH350/L, Tucson, AZ) coupled to 
an image intensifier via a 105-mm lens functioned as an area detector of the re-emitted 
light.  A circular image of the medium surface of approximately 3.4-cm diameter was 
focused onto the photocathode of the image intensifier with a 50-mm lens.  A neutral 
density filter was positioned prior to the 50-mm lens to prevent saturation of the CCD.  
A second frequency synthesizer (Programmed Test Sources, model PTS-310, Littleton, 
MA) provided an ac signal of +13-dBm, further amplified to +40-dBm using an external
amplifier (ENI, model 604L, Rochester, NY), that was used to modulate the 
photocathode of the intensifier at 100-MHz.  The synthesizers were phase locked to 
maintain a constant programmable phase offset.  Because both source and detector were 
modulated at the same frequency, a homodyne data acquisition technique was employed 
to facilitate the collection of frequency domain data.  The phase offset between 
frequency generators was swept through a 2π cycle in order to obtain phase sensitive 
intensity images that were subsequently used in an FFT analysis to obtain the quantities 
of steady-state diffuse reflectance, amplitude modulation, and phase angle (for a detailed 
description the reader is referred to reference 60).  Data acquisition and instrumentation 
control was performed on a personal computer equipped with V++ imaging software 
(Digital Optics, Auckland, New Zealand).  A schematic of the instrumentation is 
provided in Figure 4.4.
4.3.2 Scattering Media
The scattering media was comprised of 20% Liposyn (Abott Laboratories, Chicago, IL) 
diluted with distilled, deionized water to a final volume percent of 0.5%, 1.0%, and 2.0% 
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Figure 4.4.  Frequency-domain intensified charge-coupled device (ICCD) imaging 
system.  The source light provided by a laser diode (LD) is delivered through an 
optical fiber to the medium surface.  The re-emitted light passes through a neutral 
density filter (F) before being focused onto the photocathode of the image 
intensifier (I) by a lens (L1).  The intensifier is optically coupled via a lens (L2) to a 
CCD camera (C) which acquires and digitizes the images.  A frequency 
synthesizer (S1) provides an RF signal, further amplified by an external amplifier 
(A), that modulates the intensifier photocathode at 100-MHz.  A second 
synthesizer (S2) modulates the laser diode at the same 100-MHz frequency.
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to vary the degree of scattering.  The reduced scattering coefficients of the turbid media 
were measured by a colleague, Tianshu Pan, using a single-pixel frequency-domain 
technique described elsewhere74 and agree well with previously published reports.81,82
Additionally, India ink dye (Pro Art, Mt. Laurel, N.J.) was added in various 
concentrations to vary the extent of light absorption.83  The extinction coefficient for the 
India ink was determined using dilute samples in a standard spectrophotometer (SPEX 
FluoroLog, Jobin Yvon, Inc., Edison, NJ) and Beer’s Law calculations.  It was found to 
have a value of ( ) 11785 %12.1 −−= volcmink nmε .  The absorption coefficient due to the ink at 
785-nm may then be calculated as:
( )7852.303 conc. ink .%ink inka nm volµ ε  = × ×   . (4.18)
Using Eq. (4.18) it is possible to calculate the increase in the absorption coefficient as a 
result of added India ink dye as ink oa a aµ µ µ= + , where 
o
aµ  represents the absorption prior
to the addition of the dye.  In order to vary the final absorption coefficient, the 
concentration of ink was adjusted between 0% and 0.07% by volume.  Hence, a total of 
nine solutions were investigated.  Table 4.1 summarizes the composition of the nine 
solutions investigated.
4.3.3 Experimental Method
A cylindrical container constructed from clear acrylic with a diameter of 22.5-cm housed 
the Liposyn-ink solutions during the experiment.  The container was filled with the 
solution to a depth of approximately 10.5-cm yielding a final volume of approximately 
4-L.  With the source fiber located on the medium surface and the ICCD imager 
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Table 4.1.  Summary of the different media investigated.  The media were comprised of Liposyn and India ink in the 
concentrations indicated.  The range of ρ examined for each medium is listed in column 4.  Additionally, the optical 
parameters calculated via the single-pixel frequency-domain technique discussed in reference 74 are listed for each 
medium.
optical parameters determined from 
single-pixel measurements (mean ± std. 
dev.)74
solution Liposyn concentration (vol. %)
India ink concentration 
(vol. %) ρ (cm) a
µ  (cm-1) 'sµ  (cm
-1)
1 0.5 0 2.04 – 3.35 0.019 ± 0.003 5.3 ± 0.2
2 0.5 0.03 2.04 – 3.35 0.104 ± 0.001 5.9 ± 0.1
3 0.5 0.07 2.04 – 3.35 0.21 ± 0.02 6.3 ± 0.1
4 1.0 0 1.17 – 2.38 0.015 ± 0.002 10.2 ± 0.3
5 1.0 0.03 1.17 – 2.38 0.088 ± 0.001 10.4 ± 0.1
6 1.0 0.07 1.17 – 2.38 0.18 ± 0.03 10.8 ± 0.2
7 2.0 0 0.67 – 1.38 0.018 ± 0.001 22.3 ± 0.3
8 2.0 0.03 0.67 – 1.38 0.091 ± 0.001 22.3 ± 0.2
9 2.0 0.07 0.67 – 1.38 0.31 ± 0.04 21.8 ± 0.8
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positioned to acquire images from the clear cylindrical sides of the acrylic container, the 
validity of the semi-infinite medium was verified as any re-emitted light from the sides 
of the container was undetectable.
Just prior to the start of each experiment, an image was acquired of a grid to 
determine the field of view and the exact location of the fiber optic with respect to it.  
The acrylic container was then filled with a well mixed Liposyn-ink solution until the 
surface just touched the fiber tip.  The frequency domain imaging procedure then 
commenced.  A total of nine images were acquired at each of 32 equally spaced phase 
delays between the synthesizers modulating the light source and the detector.  With a 
400-msec exposure per image, data acquisition time totaled approximately 2 minutes
([exposure time / image] × [images / phase delay] × [number of phase delays]).  Hence, 
there was little concern of the solution settling due to the duration of the data acquisition.  
The procedure was repeated for all the solutions investigated.
4.3.4 Data Analysis
Frequency domain data was extracted from the phase sensitive images of the medium 
surface via a fast Fourier transform (FFT) procedure described in detail elsewhere.60
The nine images obtained per phase delay yielded nine independent area measurements 
of steady-state reflectance, modulation amplitude, and phase angle per investigational 
medium studied.  The standard deviations of the nine measurements were computed for 
use in the non-linear least-squares algorithm discussed below.  Having previously 
determined the position of the source with respect to the field of view, the data was then 
sorted into radial bins centered on the source (see Fig. 4.5).  The width of each bin was 
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Figure 4.5.  Schematic of the radial binning procedure.  (a) A total of m area 
measurements of IDC , IAC, and θ  are (b) sorted into radial bins of width ∆r = 1000-
µm.  (c) Data within each bin is averaged to yield a single measurement 
corresponding to projected distance from the source, ρ.  The number of area 
measurements, m, is dictated by the number of images obtained per phase delay, 
and n represents the number of separation distances.
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1000-µm, equivalent to the diameter of the source fiber.  Data within each bin was 
averaged to yield one measurement corresponding to its surface-projected distance from 
the source, ρ.  The first or shortest distance determined ρref, the reference position, and 
subsequent measurements of steady-state reflectance, amplitude modulation, and phase 
angle were made relative to the measurements obtained at this position.  In all cases this 
first position was ensured to be located at least 10 mean free path lengths from the 
source to preserve the validity of the diffusion approximation.80
Relative frequency domain measurements were obtained at source-detector 
separation distances ranging from 6.7-mm to 33.5-mm.  A nonlinear least squares 
analysis was then performed to fit the derived analytical solution to the obtained 
experimental measurements of steady-state reflectance, modulation amplitude, and phase 
angle in order to recover the optical properties of the medium.  Each FDPM 
measurement type could be utilized separately or in combination in the least squares 
analysis.  Thus, the parameters were extracted from the frequency-domain data sets in 
one of the following ways: ( )ρrelDCI data were fit to Eq. (4.15); ( )ωρ ,relACI  data were fit to 
Eq. (4.16); ( )ωρθ ,rel  data were fit to Eq. (4.17); ( )ρrelDCI  and ( )ωρ ,relACI  were 
simultaneously fit to Eqs. (4.15) and (4.16), respectively; ( )ρrelDCI  and ( )ωρθ ,rel  were 
simultaneously fit to Eqs. (4.15) and (4.17), respectively; ( )ωρ ,relACI  and ( )ωρθ ,rel  were 
simultaneously fit to Eqs. (4.16) and (4.17), respectively; and finally, ( )ρrelDCI , ( )ωρ ,relACI , 
and ( )ωρθ ,rel  were simultaneously fit to Eqs. (4.15), (4.16), and (4.17), respectively.  
As a result, a single FDPM data set yielded estimates of the optical parameters obtained 
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in seven different ways.  Furthermore, because essentially nine independent FDPM area 
measurements were obtained per experiment, the least-squares analysis yield nine 
estimates of the optical parameters for each of the measurement combinations employed 
in the algorithm.  The non-linear least squares fitting routine employed is part of the 
commercial package Matlab software (The MathWorks, Natick, MA).  The objective 
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where the subscript i denotes the measurement type ( relDCI , 
rel
ACI , and 
relθ ) obtained at the 
jth distance from the source, predξ  and obsξ  represent the predicted and observed 
measurements, respectively, and obsσ  is the standard deviation of the observed 
measurements.
4.4 Results and Discussion
Table 4.2 summarizes the experimentally obtained estimates for the optical parameters 
of the different media investigated.  The optical parameters are reported as the mean of 
the nine estimates obtained for each of the seven measurement combinations applied in 
the regression.  To validate the results we compare them with the values obtained using 
the single-pixel frequency-domain technique.  Although single-pixel FDPM is itself 
prone to some degree of experimental error, in general, it is regarded as a technique with 
high accuracy and measurement precision and as such, is widely used for the 
determination of optical properties of turbid media.74  Therefore, the values obtained 
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Table 4.2.  Summary of the results of the least-squares regression to determine the optical properties of the media 
investigated.  The obtained optical properties are shown along with the frequency-domain measurement type(s) that was 
(were) used in the regression.  The results shown represent the mean of nine separate trials.  The standard deviation is 
typically less than 0.006 cm-1 and 0.05 cm-1 for the absorption and reduced scattering coefficients, respectively.  The 
value nc denotes the cases where the regression algorithm did not converge on a set of optical parameters.
0% India ink 0.03% India ink 0.07% India ink
measurement(s) employed in least squares analysis aµ  (cm
-1) 'sµ  (cm
-1) aµ  (cm
-1) 'sµ  (cm
-1) aµ  (cm
-1) 'sµ  (cm
-1)
steady-state reflectance 0.003 1.70 0.009 1.48 0.006 1.21
AC amplitude 0.020 5.06 0.106 5.05 0.174 5.51
phase 0.021 5.15 0.101 4.94 0.196 5.15
steady-state reflectance and AC amplitude 0.017 5.42 0.104 5.11 0.166 5.76
steady-state reflectance and phase 0.021 5.14 0.097 4.81 0.162 4.42







steady-state reflectance, AC amplitude, and phase 0.021 5.15 0.101 4.96 0.193 5.08
steady-state reflectance 0.011 6.47 0.058 6.45 0.096 6.81
AC amplitude 0.018 9.55 0.110 9.59 0.195 10.48
phase 0.019 9.93 0.100 9.49 0.194 9.23
steady-state reflectance and AC amplitude 0.018 9.64 0.106 9.82 0.148 13.39
steady-state reflectance and phase 0.019 9.93 0.100 9.48 0.192 9.14







steady-state reflectance, AC amplitude, and phase 0.019 9.93 0.100 9.49 0.195 9.26
steady-state reflectance nc nc nc nc 0.106 11.96
AC amplitude 0.016 16.38 0.084 16.04 0.073 25.27
phase 0.021 20.89 0.122 20.41 0.276 25.76
steady-state reflectance and AC amplitude 0.016 16.33 0.083 15.98 0.081 22.75
steady-state reflectance and phase 0.021 20.89 0.122 20.40 0.276 25.74







steady-state reflectance, AC amplitude, and phase 0.021 20.89 0.122 20.41 0.276 25.75
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using the single-pixel FDPM method provide a practical metric by which to evaluate the 
accuracy of our experimental results.
The following formula is used to compute the percent relative error in the 







= × , (4.20)
where calcµ  represents the calculated optical coefficient and spµ  is the value obtained 
from the single-pixel FDPM analysis.  In general, when measurements of steady state 
diffuse reflectance were employed, either alone or in combination with another 
measurement type, the resulting optical parameters were most in error.  That is, they 
possess the highest relative error indicating that they deviate most from the optical 
parameters computed via the single-pixel technique.  This finding is in accord with the 
results of Sun et al. who also determined that simultaneous regression of relDCI  and 
rel
ACI
failed to accurately recover the optical properties.74
Table 4.3 summarizes the mean relative error in estimating the optical parameters 
for each of the measurement combinations used in the least squares analysis for all 
media investigated.  The mean relative error in determining the absorption and reduced 
scattering coefficients using DC measurements alone, as computed via Eq. (4.20), was 
approximately 64% and 54% respectively.  The addition of amplitude and phase 
measurements considerably improved this result.
Furthermore, it can be seen from Table 4.2 that measurements of steady-state 
reflectance underestimated the optical parameters.  Perhaps this is a result of the
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Table 4.3.  Mean relative errors in determining the optical properties of all semi-
infinite media investigated.  The relative error is computed using Eq. (4.20) for 
each of the measurement combinations used in the least-squares analysis.
% relative error
measurement(s) employed in least-squares analysis aµ
'
sµ
steady-state reflectance 63.7 54.3
AC amplitude 19.2 13.2
phase 14.4 10.7
steady-state reflectance and AC amplitude 20.4 13.2
steady-state reflectance and phase 16.5 12.3
AC amplitude and phase 14.6 10.7
steady-state reflectance, AC amplitude, and phase 14.6 10.7
additional signal contained in DC measurements that arises from the detection of 
ambient light.  The additional signal due to ambient light produces a greater DC signal 
collected from the medium, especially at distances further from the source.  This 
increased DC signal is incorrectly interpreted as light that has propagated and exited the 
medium.  As a result, the absorption and scattering coefficients are underestimated.  
Although precautions were made to negate extraneous light, sources of ambient light
beyond experimental control created less than ideal dark-room conditions.  Although not 
employed in the studies presented herein, in general, a background subtraction technique 
may be used to eliminate the dc intensity associated with ambient light.57 Under 
experimental conditions similar to those described within this text and employing a 
background subtraction technique, Thompson and Sevick-Muraca demonstrated that the 
ICCD imager operated in the photon-noise limit, or in terms of signal-to-noise ratio 
(SNR), the optimum in detector performance.57  Therefore, because the DC 
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measurements that were employed contained some degree of ambient light, a resulting 
decrease in SNR could explain the less precise DC measurements.
In addition, because the least-squares regression utilized an optimization function 
weighted by the standard deviations of obtained measurements, and the obtained 
measurements of relDCI  were generally less precise than measurements of 
rel
ACI  and 
relθ
( θσσσ ,ACDC II > ), the analyses that employed a combination of measurements favored 
measurements of relACI  and 
relθ  over measurements of relDCI .  That is, like the conclusions 
made by Sun et al.,74 the results indicate that simultaneous regression of relDCI  ,
rel
ACI , and 
relθ  data gives comparable recovered results as simultaneous regression of relACI  and 
relθ .  
Consequently, the estimates of the optical parameters were minimally influenced by the 
addition of relDCI  measurements in the least-squares analysis.
On the other hand, because modulation amplitude and phase lag measurements 
are independent of ambient light conditions and were obtained with greater precision, the 
optical parameters determined from measurements of relACI  and 
relθ  either alone or in 
combination deviated least from the values obtained using the single-pixel FDPM 
technique.  Typically, the use of phase measurements alone or in combination with 
measurements of modulation amplitude resulted in the determination of the optical 
parameters that most closely matched the values determined by the single-pixel 
frequency-domain analysis.  The mean relative error, as computed by Eq. (4.20), was 
approximately 15% and 11% in the determination of the absorption and reduced 
scattering coefficients, respectively, for both cases.  In addition, the calculated 
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absorption coefficients agreed quite well with those computed using the added absorber 
calculation provided by Eq. (4.18).
Figure 4.6 shows the experimentally acquired relDCI  measurements and the 
corresponding predicted values obtained from a least-squares analysis using





















0.5% Liposyn − observed data
1.0% Liposyn − observed data
2.0% Liposyn − observed data
0.5% Liposyn − least squares fit
1.0% Liposyn − least squares fit
2.0% Liposyn − least squares fit
Figure 4.6.  Experimentally obtained measurements of normalized IDC intensity 
(a.u.) as a function of distance from the source (cm) for solutions containing 
various concentrations of Liposyn emulsion and no added ink absorber.  The 
symbols and error bars denote the mean and standard deviations of the 
measurements, respectively, whereas the lines represent the results of a least-
squares analysis that employed IAC and θ measurements to determine the optical 
parameters.
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measurements of relACI  and 
relθ  collectively for media comprised of various 
concentrations of Liposyn and no added ink absorber.  The plot demonstrates the degree 
to which the obtained steady-state reflectance measurements deviate from diffusion 
theory over the distances investigated.  Similarly, Figures 4.7 and 4.8 report the





















0.5% Liposyn − observed data
1.0% Liposyn − observed data
2.0% Liposyn − observed data
0.5% Liposyn − least squares fit
1.0% Liposyn − least squares fit
2.0% Liposyn − least squares fit
Figure 4.7.  Experimentally obtained measurements of normalized IAC intensity 
(a.u.) as a function of distance from the source (cm) for solutions containing 
various concentrations of Liposyn emulsion and no added ink absorber.  The 
symbols and error bars denote the mean and standard deviations of the 
measurements, respectively, whereas the lines represent the results of a least-
squares analysis that employed IAC and θ measurements to determine the optical 
parameters.
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0.5% Liposyn − observed data
1.0% Liposyn − observed data
2.0% Liposyn − observed data
0.5% Liposyn − least squares fit
1.0% Liposyn − least squares fit
2.0% Liposyn − least squares fit
Figure 4.8.  Experimentally obtained measurements of referenced phase lag 
(radians) as a function of distance from the source (cm) for solutions containing 
various concentrations of Liposyn emulsion and no added ink absorber.  The 
symbols and error bars denote the mean and standard deviations of the 
measurements, respectively, whereas the lines represent the results of a least-
squares analysis that employed IAC and θ measurements to determine the optical 
parameters.
experimentally acquired measurements of relACI  and 
relθ , respectively, as well as the 
corresponding predicted values obtained via a simultaneous least-squares analysis of 
rel
ACI  and 
relθ  data for media comprised of various concentrations of Liposyn and no
added ink absorber.  Unlike Figure 4.6, these plots demonstrate that measurements of 
amplitude modulation and phase lag agree relatively well with theoretical predictions.  
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The results for the solutions containing added India ink absorber are akin to Figures 4.6, 
4.7, and 4.8.
Finally, to investigate the effect of modulation frequency on the determination of 
the optical properties, measurements were performed at three additional distinct
modulation frequencies (40-MHz, 60-MHz, and 80-MHz) for the solution comprised of 
0.5% Liposyn.  The gathered relACI  and 
relθ  data were then employed in the least squares 
analysis to obtain estimates for the optical parameters.  Figure 4.9 presents the obtained
absorption and reduced scattering coefficients as the mean of nine separate trials.  The 
estimates at modulation frequencies of 40-MHz, 60-MHz, and 80-MHz are consistent 
with the results obtained at a modulation frequency of 100-MHz.  Again, the obtained 
absorption coefficients were found to deviate from the value obtained via the single-
pixel technique by on average approximately 17% over all the modulation frequencies 
investigated.  Similarly, the reduced scattering coefficient was found on average to 
within 2% of the single-pixel value.
4.5 Conclusion
Herein the use of an ICCD detector for the collection of frequency-domain photon 
migration data and its subsequent use in determining the optical properties of semi-
infinite turbid media has been demonstrated.  Referenced measurements obtained at 
multiple source-detector positions and the diffusion approximation were employed to 
regress estimates for the absorption and reduced scattering coefficients.  The results 
indicate that measurements of steady-state diffuse reflectance were least accurate in 
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Figure 4.9.  Estimates of the optical parameters of a solution comprised of 0.5% 
Liposyn and no added ink absorber.  The optical parameters were acquired via a 
least-squares analysis using measurements of modulation amplitude and phase lag.  
The experiments employed the various modulation frequencies listed in the first 
column of the table.  The symbols denote the mean of nine estimates while the 
error bars indicate the standard deviations.
determining both the absorption and reduced scattering coefficients, with estimates 
varying from values calculated by an independent single-pixel FDPM technique by on 
average approximately than 64% and 54%, respectively.  Furthermore, the results 
suggest that measurements of phase lag provide the most accuracy in determining optical 
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parameters when a single type of measurement is employed; phase lag measurements 
yielded estimates for the absorption and reduced scattering coefficients that varied by on 
average approximately 14% and 11% , respectively.
The least-squares regression algorithm that was employed could exploit multiple 
measurement types simultaneously.  The results deviated most from the estimates 
obtained via single-pixel FDPM technique when the combinations of measurements 
included steady-state reflectance.  This is due in part to the detection of ambient light 
and it is believed that employing a background subtraction technique should improve the 
results.  On the other hand, the most accurate estimates of the optical parameters were 
obtained when amplitude data were employed along with phase lag data.  In this case, 
the estimates for the absorption and reduced scattering coefficients again varied from 
values computed by the single-pixel technique by on average approximately 15% and 
11%, respectively.  Finally, it was determined that the results were consistent at multiple 
modulation frequencies spanning 40 – 100-MHz.  In summary, it is recommended that 
the optical properties of semi-infinite media be obtained from an analysis of phase shift 
data or the simultaneous regression of amplitude and phase shift data.
As a final note, the estimates obtained for the accuracy of the derived optical 
parameters were calculated using reference values, that themselves, were obtained from 
an independent experimental technique.  As a result, because the true optical properties 
of the media investigated were unknown, the accuracy of the results that were obtained 
can in fact represent a conservative estimate.  Nonetheless, this study demonstrates for 
the first time the use of an ICCD detection system to acquire simultaneous surface area 
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FDPM measurements for purposes of estimating the absorption and scattering 
coefficients of turbid media.  Additionally, the results validate the use of an ICCD 
detection system for FDPM analysis on systems that exhibit tissue-like scattering.
With the validating studies completed, the ICCD imaging system was transported 
to M.D. Anderson Cancer Center in Houston, Texas and the research focus turned to the 
evaluation of fluorescent contrast agents for diagnostic imaging of cancer.  Beginning 
with the following section, experimental work on in vivo fluorescence imaging of cancer 
in animal subjects is discussed.  
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5. PHARMACOKINETICS OF ICG AND HPPH-CAR FOR THE 
DISCRIMINATION OF TUMOR TISSUE IN A CANINE MODEL*
Although the work presented in this section chronologically preceded the development 
of the imaging system described in the previous sections, it represents the first clinical 
studies of fluorescence imaging on animals conducted by the Photon Migration 
Laboratories, and as such, appears as the first section of experimental fluorescence 
imaging in vivo.  The studies were conducted as a collaborative effort at the Lovelace 
Respiratory Research Institute in the summer of 1998, several months prior to the 
author’s joining the research group.  Thus, experimental data collection, animal care, and 
preparation of fluorescent dyes was performed by colleagues and collaborators who are 
gratefully acknowledged and individually recognized in the Acknowledgments section 
located in the preamble to this dissertation.  Although the data was obtained by 
colleagues, the pharmacokinetic analysis of the data was performed entirely by the 
author and represents the first time pharmacokinetics of fluorescent contrast agents have 
been used to discriminate diseased from normal tissue.  The work presented in this 
section culminated in its publication in Photochemistry and Photobiology.
* Reprinted in part with permission from “Pharmacokinetics of ICG and HPPH-car for the detection of 
normal and tumor tissue using fluorescence, near-infrared reflectance imaging: a case study,” by M. 
Gurfinkel, A. Thompson, W. Ralston, T. Troy, A. Moore, T. Moore, J. Gust, D. Tatman, J. Reynolds, B. 
Muggenburg, K. Nikula, R. Pandey, R. Mayer, D. Hawrysz, and E. Sevick-Muraca, 2000.  Photochemistry 
and Photobiology, 72, 94-102.  Copyright 2000 by the American Society for Photobiology.
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5.1 Introduction
Numerous investigators have proposed developing non-invasive diagnostic optical 
approaches to detect cancer and to monitor local photosensitizer concentrations for 
effective staging of photodynamic therapy (PDT).58,84-86  Owing to a photosensitizer's 
near-infrared (NIR) absorption and emission in the therapeutic wavelength regime where 
light penetrates several centimeters of tissue, it is possible to sense and quantitate 
photosensitizer concentration in subsurface tissues from measurements of diffuse light 
propagation.87-89  Still other investigators propose to use diffuse NIR light to detect and 
image diseased subsurface tissues based upon spatial variations in NIR absorbance, 
fluorescence, and fluorescence decay kinetics associated with photodynamic therapy 
(PDT) and other fluorescent agents (for review the reader is referred to reference 90).  
Previous work has demonstrated the use of frequency-domain photon migration (FDPM) 
with image-intensified CCD detection in order to image in-vivo diseased tissues using 
fluorescent contrast agents.91  FDPM techniques may offer added imaging advantages in 
that they enable additional image contrast based upon changing fluorescence decay 
kinetics of exogenous agents.14,92  Cubeddu and coworkers have also demonstrated 
lifetime-based detection of surface lesions using time-domain approaches.93 The work 
presented in this section demonstrates the use of image-intensified CCD continuous 
wave imaging as a function of time (on the order of minutes) to collect fluorescent 
emissions from photodynamic and fluorescent contrast agents, allowing the subsurface 
differentiation of normal from diseased tissue volumes based on the pharmacokinetics of 
the therapeutic or diagnostic agent in question.  The results are presented to further 
93
reinforce the potential use of photodynamic agents as optical imaging contrast agents for 
the detection of subsurface tissues.
In the following sections, the pharmacokinetic models used for modeling the 
uptake and wash-out of ICG and HPPH-car are presented.   The method used to obtain 
the parameters underlying the pharmacokinetic models from measurements of 
fluorescent intensity at discrete points on the tissue surface is discussed.  The fluorescent 
agents and animal model employed in the study are described and the image-intensified 
CCD camera system used to collect fluorescent images of canine mammary tissues is 
outlined.  A statistical comparison of parameter estimates for presumed normal and 
diseased tissues is provided and compared to pathology.  Finally, the maps of 
pharmacokinetic parameter estimates are provided to differentiate normal from diseased 
tissues based on the variation in pharmacokinetics. 
5.2 Theory
5.2.1 Pharmacokinetics for ICG
Based on experimental measurements, ICG was observed to exhibit rapid wash-in and 
wash-out, thereby requiring a double-exponential, four-parameter model. 
( ) ( ) ( )tBtAtI βα −+−= expexp  (5.1)
where parameters A, B, α, and β are the pharmacokinetic parameters describing the 
uptake and release of ICG.  To underscore the physical significance of these model 
parameters, the pharmacokinetic model for the distribution of ICG between blood and 
tissue is illustrated in Figure 5.1.
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Figure 5.1.  ICG pharmacokinetic model.
The concentrations of dye in the blood, CB, and tissue, CT, are functions of time, 











where elpB kkk += , pk and rk are first order rate constants that represent the tissue 
wash-in and wash-out rates, respectively, and elk is the first order rate constant that 
represents the rate at which dye is removed from the circulation through all other routes.  
At 0=t  (injection time), 
oBB
CC = and 0=TC .  The solution to this system of
differential equations forms the basis of the model.











= expexp , (5.4)
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( ) ( )tkCtkCC pBopBoT αβαββα −−−−−= expexp , (5.5)









 −+−+= elrBrBr kkkkkk 42
1 2β . (5.7)
The observed fluorescence intensity, I(t), is a weighted sum of the concentration of 
contrast agent in the blood and tissue compartments and is represented by:
( ) TB CwCwtI 21 +≅ (5.8)
Combining Eqs. (5.4), (5.5), and (5.8) yields:
( ) ( )[ ] ( )






















Comparing Eqs. (5.1) and (5.9) the pharmacokinetic parameters for ICG may be 
expressed as:
( )[ ]21 wkkwCA prBo −−−= αβα , (5.10)
( )[ ]21 wkkwCB prBo +−−−= ββα , (5.11)
and the complex rate constants α  and β  which were previously defined in Eqs. (5.6) 
and (5.7).  
Since ICG is a blood pool or blood persistent agent without selective uptake into 
tumor or other diseased tissues, kp and kr should be equivalent for normal and diseased 
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tissues.  Hence, the sum of α and β, or kp+kr+kel, should also be equivalent for normal 
and diseased tissues, assuming kel, or the combined liver and kidney ICG uptake rate, is 
also tissue independent.  On the other hand, since vascular density is enhanced in tumor 
regions, greater ICG fluorescent intensity would be observed in these regions.  Therefore, 
the differentiation of normal from diseased tissues by a blood pool or blood persistent 
agent results only from variations in microvessel density, not from differences in 
selective uptake or efflux mechanisms.
5.2.2 Pharmacokinetics for HPPH-car
Unlike ICG, net wash-out of HPPH-car was not observed over the 10-30 min. range of 
measurements.  This observation enabled reduction of the pharmacokinetic model, 
illustrated in Figure 5.2, to a single exponential, three- parameter model.
( ) [ ] BtKAtI B +−= exp (5.12)











B 2= . (5.14)
Fitting the HPPH-car fluorescence intensity to a double-exponential model 
yielded a zero or near-zero coefficient inside the second exponential function reported in 
Eq. (5.1), thereby supporting the hypothesis that a single-exponential model is applicable
for the HPPH-car case.  Equations (5.13) and (5.14) were obtained by setting kr equal to 
zero in Eqs. (5.10) and (5.11), respectively.  Since it is assumed that selective uptake of
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Figure 5.2.  HPPH-car pharmacokinetic model.
HPPH-car into the tumor region occurs94, kp should be greater in tissue regions 
associated with disease.  Since kel, which describes the clearance of HPPH-car owing to 
kidney and liver function, is also assumed to be equivalent for normal and diseased 
tissues, we would expect that mapping kB would discriminate the adenocarcinoma from 
normal tissue
Having derived the above models describing the pharmacokinetics of ICG and 
HPPH-car within tissues, we then fit these models to the temporal variation of
fluorescent intensity acquired from the surface of mammary tissues.  In addition to the 
pharmacokinetic parameters, the fitting routine also calculates the sum of the relative 
error at each pixel point (i, j) to assess the accuracy of the models presented.











5.3 Materials and Methods
5.3.1 Fluorescent Contrast Agents and Animal Model
The work in this section primarily focuses on a pharmacokinetic analysis of dynamic 
fluorescence data for evaluation of contrast agents and diagnostic imaging.  However, 
for completeness, the salient features of the fluorescent dyes and animal model are 
discussed herein.  For more information about the contrast agents and canine model of 
spontaneous breast cancer, the reader is referred elsewhere.95,96  As alluded to earlier, the 
following work was performed at the Lovelace Respiratory Research Institute, an 
institute fully accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care International, and all studies were performed under the 
appropriate guidelines.
Two fluorescent dyes were used to detect spontaneous tumors within the canine 
mammary chain.  The first, indocyanine green (ICG) (Cardio-Green, Becton-Dickenson 
Microbiology Systems, Cockeysville, MD) with excitation and emission peaks near 
780-nm and 830-nm, respectively, was reconstituted with sterile water for injection and 
administered intravenously (i.v.) at 1 mg kg-1 body weight.  Previously, the extinction 
coefficient of a micromolar solution of ICG in water at 780-nm was determined to be 
130,000-M-1cm-1; at 830-nm its fluorescence quantum efficiency and lifetime were 
found to be 0.016 and 0.56-ns, respectively.14
The second fluorescent agent studied was HPPH-car.  HPPH-car consists of the 
photosensitizer HPPH conjugated with a carotene moiety in order to reduce or eliminate 
phototoxicity for consideration of its potential use as a diagnostic-imaging agent (R.K. 
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Pandey and A.N. Kozyrev, unpublished).  Without the carotene moiety, HPPH is an 
effective photosensitizer97,98 and is currently in phase I/II clinical trials at Roswell Park 
Cancer Institute, Buffalo, NY.  It has been previously examined for the fluorescence 
detection of tumors in hamsters and rats.99  HPPH-car fluorescence was detected at 
710-nm following 660-nm excitation.  The extinction coefficient at 664-nm was 
determined to be 45,000-M-1cm-1; its fluorescence quantum efficiency and lifetime were 
found to be 0.15 and 3.2-ns, respectively.95 For administration, HPPH-car was 
formulated in a 1% Tween-80 and 5% dextrose solution and injected i.v. at 0.3 mg kg-1.
The pharmacokinetics of ICG and HPPH-car were studied simultaneously in an 
11 year–old female beagle, weighing 4.55 kg and in apparent good health, that presented 
evidence of palpable mammary masses in the right fourth (R4) mammary gland. For 
injection of contrast agent and subsequent imaging, the animal was fasted for 18-hr. The 
animal was placed under general anesthesia, administered an i.v. injection of ICG, and
subsequently imaged. The fully recovered animal was then again anesthetized 48-hr 
after ICG injection for HPPH-car injection and subsequent imaging.  At a later date,
surgical excision of the mammary tumors was performed for curative reasons and 
pathologic examination. As described below, the different excitation and emission 
spectra for the two contrast agents allowed identification of ICG separately from 
HPPH-car within the tissues.
5.3.2 ICCD Imaging Setup and Instrumentation
Figure 5.3 illustrates the experimental apparatus used to obtain area, fluorescent, DC 
measurements59,91,100 from the surface of the canine subject.  For front illumination 
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Figure 5.3.  Instrumentation for the multipixel imaging device.
geometry, collimated light from a 25-mW, 778-nm laser diode (Melles Griot model 
06DLS403, Boulder, CO) or a 100-mW, 660-nm laser diode (Philips Optoelectronics, 
Eindhoven, Netherlands) is expanded to illuminate a circular area approximately 4-cm in 
diameter on the surface of a plexiglass plate, which slightly compresses the subject's 
mammary tissue to minimize motion artifacts and to create a flat imaging surface.  A 
laser diode driver (Melles Griot model 06DLD203, Boulder, CO) maintains the diode at 
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a constant DC bias and temperature.  Located directly above the plexiglass plate, a 
50-mm Nikon camera lens and an interference filter combine to focus only diffuse 
830-nm (ICG) or 710-nm (HPPH-car) fluorescent light onto the photocathode of an 
image intensifier (Generation III FS9910C, Roanoke, VA).  The 50-nm bandwidth 
between excitation and detected emission sufficiently prevents leakage of excitation 
light through the interference filter.  A refractive index matching gel couples the image 
intensifier's phosphor screen to a fiberoptic bundle, which transmits the intensified, 
diffuse fluorescent image to a 512 × 512 CCD detector array (Princeton Instruments 
model TE/CCD-512-EFT, Trenton, NJ).  To minimize the detection of any inherent dark 
current, the CCD unit is cooled to −30°C.  The multi-pixel imaging device is affixed to a 
sliding rack assembly that permits three-dimensional movement of the camera over the 
subject's mammary tissue.
5.3.3 Data Acquisition and Analysis
Directed by a Labview data acquisition program (National Instruments Corp., Austin, 
TX), the CCD camera acquires ten fluorescent, DC images using an exposure time of
0.2-sec for each image.  Subsequently, the program averages these images and stores a 
binned 128 × 128 intensity array into a data file.  Following a 10-sec delay, the program 
repeats the same data acquisition procedure.  Data acquisition continues until the
intensity arrays from several successive averaged images are relatively unchanged, 
indicating the approach of steady state.  Following the completion of data acquisition 
from the canine model, Matlab (The Mathworks, Inc., Natick, MA) further bins the 
images down to 64 × 64 intensity arrays to expedite the pharmacokinetic analysis.  The 
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images are stored in 64 × 64 × n arrays, where the nth dimension corresponds to the time 
at which the averaged image was stored.
A Matlab curve fitting routine is then employed to fit the intensity data at each 
pixel within the three-dimensional array to a kinetic model describing the uptake and 
release of contrast agent.  While the fluorescent intensity at each pixel is proportional to 
the presence of contrast agent, the intensity is also mediated by tissue optical properties 
of scattering and absorption.  Separate, ongoing research seeks to map the concentration 
and fluorophore decay kinetics in three-dimensional tissue volumes.101,102  However, in 
this study the tissue optical properties are assumed to be relatively constant, so that the 
temporal fluorescence intensity may be monitored to obtain information regarding dye 
pharmacokinetics.
5.4 Results and Discussion
The animal model used in this study is the naturally occurring canine mammary tumor.  
These tumors occur in dogs as they age.  The tumors have many characteristics similar
to mammary tumors in women.  The occurrence of such tumors in bitches in the source 
colony for this study have been described elsewhere.96
Figure 5.4(a) and 5.4(b) illustrate example results from fitting the ICG and 
HPPH-car pharmacokinetic models, respectively, to time-dependent fluorescent intensity 
acquired from specific pixels located within the binned 64 x 64 CCD detector array.  
Figures 5.5 and 5.6 present pharmacokinetic parameter maps for ICG and HPPH-car, 
respectively, for the entire detector domain, while Figure 5.5 additionally displays a map 
of βα + .  Both figures also report the sum of the relative error as defined by Eq. (5.15).
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Figure 5.4.  Fluorescence intensity as a function of time illustrating typical curve 
fits using the (a) ICG pharmacokinetics model and (b) HPPH-car 
pharmacokinetics model.
For ICG pharmacokinetics, the tumor region corresponds to the maximum of the 
B and β maps, Figures 5.5(b) and 5.5(d), respectively, and the minimum of the A map,
Figure 5.9(a).  Upon inspection of Eq. (5.1), one observes that it is difficult to relate 
these parameter estimates to important physiological parameters such as the fraction of 
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Figure 5.5.  ICG pharmacokinetic parameter maps of (a) A (a.u.), (b) B (a.u.), (c) α
(sec-1), (d) β (sec-1), (e) α + β (sec-1), and (f) sum of the relative error.
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Figure 5.6.  HPPH-car pharmacokinetic parameter maps of (a) A (a.u.), (b) B (a.u.), 
(c) Bk  (sec
-1), and (d) sum of the relative error.
vascular and extravascular space (w1 and w2, respectively) or net uptake of ICG (i.e., kp
and kr).  Nonetheless, these parameter maps could correspond to high vascular volumes
associated with disease.  As depicted in Figure 5.5(e), the addition of α and β does not 
seem to differentiate normal tissues from the diseased ones.  Since α + β relates to the 
sum of tissue uptake parameters, it is probable that the non-selective, net uptake of ICG 
occurs through equivalent mechanisms in normal and diseased tissues.
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Figures 5.6(a) and 5.6(b) do not illustrate any demarcation of the 
adenocarcinoma from the maps of parameter A and the pre-exponential factor B found in 
the HPPH-car model. However, Figure 5.6(c) confirms the assumption that the rate
constant describing the net uptake of HPPH-car, Bk , does indeed discriminate diseased 
from normal tissues.  The region of increased Bk  corresponds to the tissue region 
containing the adenocarcinoma.
Twenty pixel points, equally distributed between regions that pathology reported 
to be normal and diseased tissues, were arbitrarily chosen in order to statistically 
compare the pharmacokinetic parameters for ICG and HPPH-car associated with these
tissues.  Figures 5.7(a) and 5.7(b) depict the exact location of the pixel points used in 
these analyses; Tables 5.1 and 5.2 list their pharmacokinetic model parameter estimates.
Figure 5.7.  Pseudocolor plot of fluorescent DC intensity, midpoint of the data 
acquisition, denoting the location of pixels used in the statistical analysis for (a) 
ICG and (b) HPPH-car.
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Table 5.1.  ICG pharmacokinetic parameter values at designated pixel locations.
pixel A (a.u.) B (a.u.) )(sec10 12 −×α )(sec10 14 −×β )(sec 1−+βα
Adenocarcinoma 
region 
(40,26) -4226 4214 1.28 1.50 0.0130
(43,27) -3536 3637 1.41 1.42 0.0142
(47,28) -3842 3958 1.39 1.33 0.0140
(49,30) -3582 3699 1.32 1.25 0.0133
(51,32) -3233 3395 1.32 1.17 0.0133
(45,28) -3848 3950 1.34 1.42 0.0135
(38,26) -3812 3913 1.30 1.42 0.0131
(50,28) -3371 3535 1.67 1.17 0.0168
(51,34) -3233 3453 1.24 1.17 0.0125
(52,30) -3347 3501 1.61 1.17 0.0162
mean -3603 3726 1.39 1.30 0.0140
Presumably normal 
tissue region
(10,20) -771 1098 1.87 0.544 0.0188
(20,45) -806 1105 1.55 0.744 0.0156
(25,35) -798 1114 1.47 0.754 0.0148
(40,9) -826 1158 0.68 0.776 0.0069
(45,55) -456 830 1.99 0.502 0.0200
(5,35) -489 862 1.74 0.570 0.0174
(35,55) -549 910 2.08 0.489 0.0208
(20,10) -487 874 0.51 0.598 0.0052
(15,53) -346 736 2.05 0.387 0.0205
(50,50) -556 938 1.33 0.547 0.0134
mean -608 962 1.53 0.591 0.0153
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Table 5.2  HPPH-car pharmacokinetic parameter values at designated pixel 
locations.
pixel A (a.u.) B (a.u.) )(sec10 15 −×Bk
Adenocarcinoma 
region
(16,32) -396 870 268
(20,31) -467 963 267
(23,31) -447 912 257
(25,29) -476 948 248
(27,27) -431 890 252
(19,30) -441 931 231
(17,31) -413 901 229
(26,28) -450 923 266
(23,29) -473 955 228
(14,31) -392 870 228
mean -439 916 247
Presumably normal 
tissue region
(25,10) -336 772 34.2
(35,50) -709 1154 3.99
(45,35) -79 534 47.5
(55,22) -1993 2440 1.60
(45,45) -8431 8890 0.389
(40,7) -9663 10105 0.424
(50,28) -11352 11795 0.389
(28,57) -4977 5443 0.389
(13,12) -1392 1814 5.12
(59,41) -3856 4327 0.507
mean -4279 4727 9.45
A Student’s t test was performed to determine if α+β, the sum of parameters 
found in the ICG pharmacokinetic model, varied significantly between tumor and 
presumably normal tissue.  The 95% confidence limits of α+β for these tissues 
overlapped, indicating no significant difference in net uptake kinetics between the two 
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tissues.  Thus, it may be concluded that it is not possible to discriminate different types 
of tissue based on the parameter α+β, or the net uptake kinetics of ICG.  Similarly, a 
student’s t test was performed on Bk  to determine if the pharmacokinetics of HPPH-car 
can be employed to differentiate normal from diseased tissues.  Unlike ICG, the analysis 
reported at a 95% confidence limit that the values for Bk  associated with tumor and 
presumably normal tissues did not overlap.  Thus, it is reasonably assumed that the net 
uptake kinetics of HPPH-car may indeed be used to demarcate diseased tissues.
The mechanisms that mediate the preferential accumulation of fluorescent dye in 
neoplastic tissue relative to normal tissue is still not completely understood but may
depend on a number of factors including, but not limited to, the nature of the dye itself, 
the normal tissue being considered, and in the laboratory setting, the animal tumor model 
being investigated.94  It is hypothesized that ICG accumulates in regions of tissue 
possessing leaky vasculature.  Although leaky vasculature often accompanies tumor 
proliferation, accumulation of ICG may not be limited to neoplastic tissue.  ICG would 
also be expected to amass in bruised or injured regions of the tissue volume.  On the 
other hand, HPPH-car is presumed to accumulate in tumor tissue by a different 
mechanism.  HPPH belongs to a group of compounds known as photosensitizers, which 
are believed to selectively accumulate in tumor tissues.  The specificity may be mediated 
by the dye's association with low-density lipoproteins (LDL) and the upregulation of 
LDL receptors in tumor cells, which presumably results from an increased rate of cell 
proliferation or an increased rate of membrane turnover without proliferation.94
Therefore, it is plausible that, as opposed to ICG, the uptake mechanism of HPPH-car 
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suggests a more specific interaction; that is, strong HPPH fluorescence should be 
detected only in regions of the tissue volume where an abundance of cells (presumably
malignant cells) overexpressing LDL receptors are present.
5.5 Summary
The work presented in this section demonstrates the use of red-fluorescing dyes to 
differentiate normal from diseased tissues using simple CW fluorescence intensity 
imaging and pharmacokinetic analysis.  While the excitation and emission spectra of 
HPPH-car overlap with melanin, perhaps limiting the ability to deliver excitation light 
and successfully detect propagated fluorescence light at the tissue surface, the dye 
nonetheless possesses net uptake rates that over the time course of the measurements can 
be used to differentiate normal from diseased tissues.  While ICG has more favorable 
excitation and emission spectra than HPPH-car, its non-selective net uptake may not be 
feasible for the detection of disease.  Ongoing work seeks to adapt tissue surface 
fluorescence measurements made with the modulated image-intensified CCD camera 
described in part herein and elsewhere91 with mathematical models for determining local 
dye concentration and fluorescence decay kinetics.101,102  With the ability to provide 
time-dependent, three-dimensional mapping of dye concentration, the ability to 
individually tailor photodynamic therapy for maximal efficiency is promised by this
work as well as the work of several other investigators.  Upon using PDT agents 
modified to reduce therapeutic action, diagnostic imaging may be possible.  Finally, the 
ability to determine the in-vivo dye fluorescence decay kinetics could aid in the detection 
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of disease, by providing biochemical specificity as pointed out by Cubeddu and 
coworkers93, as well as in determining the potential toxicity of photodynamic agents.
The work presented in this section demonstrates that pharmacokinetic analysis 
can be a powerful tool for the evaluation of contrast agents, specifically those designed 
to target molecular markers of disease.  Building on the results presented in this section, 
the following section describes a three-compartmental pharmacokinetic analysis of in 
vivo fluorescence conducted on a murine model of carcinoma to evaluate a novel 
integrin-targeted fluorescent contrast agent.
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6. IMAGING PHARMACOKINETICS OF MOLECULARLY TARGETED 
DIAGNOSTICS AND THERAPEUTICS: IN VIVO PHARMACOKINETICS OF 
αVβ3 INTEGRIN– TARGETED OPTICAL CONTRAST AGENT
Building upon the results of the previous section, the experimental studies described in 
this section are intended to evaluate the molecular specificity of a molecularly targeted 
fluorescent dye.  As in the previous section, the focus of the work herein is not on the 
development of the contrast agent itself, but rather on the use of dynamic fluorescence 
imaging and pharmacokinetic analysis to evaluate the specificity of the integrin-targeted 
fluorescent contrast agent in an animal model of carcinoma.  Again, the work was 
performed as a collaborative effort, with the experimental studies conducted at the 
University of Texas M.D. Anderson Cancer Center (MDACC) in Houston.  
Collaborators at MDACC, recognized in the Acknowledgements section in the preface 
of this dissertation, were responsible for the synthesis of the contrast agents and the 
preparation of the animal models of carcinoma.  Therefore, the experimental aspects 
related to the contrast agents and animal models are discussed only briefly for 
completeness.  
6.1 Introduction
The targeted delivery of therapeutic agents represents a novel approach in the treatment 
of cancer.  Unlike conventional treatment strategies such as chemotherapy and radiation 
therapy, targeted therapies are designed to treat and kill only the affected cancerous cells, 
thereby reducing toxicity to normal, non-cancerous cells.
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In the past several years, a number of targeted cancer drugs have shown
tremendous promise and a select few have been approved by the Food and Drug 
Administration (FDA).  These cancer drugs generally target and inhibit signal 
transduction that would otherwise lead to the proliferation, differentiation, or anti-
apoptosis of the cancer cells.  The drug is often targeted to an extracellular membrane 
bound receptor or to an intracellular protein critical to the signaling pathway, resulting in 
the interruption of the downstream signaling cascade.103  Herceptin®, developed by 
Genentech, Inc. and approved by the FDA in 1998, exerts its therapeutic effects on 
metastatic breast cancer cells that overexpress the HER-2 receptor.103-105  Similarly, 
Erbitux®, developed by ImClone Systems Inc., targets the extracellular membrane-bound 
epidermal growth factor receptor, commonly overexpressed in many types of 
cancer.104,105  More recently, the protein-tyrosine kinase Bcr-Abl, whose elevated 
activity is strongly implicated in the mechanism of development of chronic myeloid 
leukemia, has been the molecular target of a therapeutic drug.106  The drug, Gleevec®, 
marketed by Novartis Pharmaceutical Corporation in 2001, competitively binds the ATP 
binding site on the enzyme, and suppresses the proliferation of Bcr-Abl-expressing 
cells.103-106
Integrins, a group of transmembrane glycoproteins that bind cells to the 
extracellular matrix, constitute another family of cell surface receptors that represent a 
possible target for site-specific drug delivery.  Given that many of the extracellular 
proteins recognized and bound by integrins share the amino acid sequence arginine-
glycine-aspartic acid (RGD) and integrins are often overexpressed on actively 
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proliferating endothelium as compared to quiescent endothelium cells, RGD tags could 
serve to deliver therapeutic agents to highly angiogenic sites.  Schiffelers et al. recently 
demonstrated the use of an RGD-peptide conjugated to a liposome encapsulating the 
drug doxorubicin to target the αvβ3 integrin and inhibit tumor growth in a murine colon 
carcinoma model.107  Although it is unlikely that the targeted treatment of cancer will 
find the widespread applications of conventional approaches in the all too near-future, 
targeted therapy marks a significant advance in the drive towards patient-specific cancer 
treatment regimens.
In addition to targeting therapeutic agents, researchers have exploited tumor-
specific molecular targets for purposes of imaging.  Both nuclear108,109 and optical 
imaging21,22,24,30,110 techniques have exploited receptor overexpression to visualize 
tumors.  Furthermore, Weissleder and colleagues demonstrated the use of optical 
imaging to visualize tumors following the enzyme specific activation of a near-infrared 
fluorescent probe.33  Relative to nuclear imaging, optical imaging requires the 
administration of ultra-low concentrations of diagnostic agent.  This fact, combined with 
the ability to acquire rapid dynamic optical images, enables optical imaging to serve as a 
diagnostic tool for the evaluation of pharmacokinetic properties of agents targeted 
towards molecular markers of disease.
Because targeted therapies are beneficial to select patient populations, the need 
for a diagnostic tool capable of assessing expression levels of target receptors and 
providing exclusion criteria precedes the successful implementation of this paradigm.  
To this end, the use of in vivo pharmacokinetic analyses to evaluate the specificity of a 
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targeted diagnostic agent is demonstrated, from which one may infer receptor-ligand 
affinity, receptor expression levels, and receptor turnover rate.  The diagnostic agent, a 
conjugate of RGD peptide and a fluorescing cyanine dye, RGD-Cy5.5, is targeted to the 
αvβ3 integrin overexpressed on xenografted tumors in a murine model of human 
Kaposi’s sarcoma, KS1767.
6.2 Theory
In this section a pharmacokinetic model is developed in order to describe the time-
dependent distribution of the fluorescing dye-peptide conjugate throughout the animal.  
The model, depicted schematically in Figure 6.1, is comprised of three compartments: 
the blood plasma compartment, the extravascular, extracellular compartment, and the 
cellular compartment.
The dye is administered rapidly into the blood plasma compartment via an 
intravenous bolus injection.  From this central blood compartment, the dye diffuses 
across the vascular endothelium and partitions into the extravascular, extracellular space 
Figure 6.1.  Schematic depicting the three-compartment pharmacokinetic model.
116
(EES) represented by the second compartment.  The endothelial transfer coefficient or 
the rate constant for the distribution of dye from the blood to the EES is given by kp
while kr is the rate constant describing the reflux from the EES to the blood.  A measure 
of vascular permeability can be obtained from an analysis conducted on first pass 
circulation data, or data obtained immediately following the bolus injection of the agent.  
Cuccia et al. employed a pharmacokinetic analysis to quantify physiologic parameters 
related to capillary permeability following the administration of the non-specific dye 
indocyanine green.111
In addition to extravasation into the EES, the dye is eliminated from the blood 
compartment via other routes such as kidney filtration and liver metabolism, described 
collectively by the rate constant kel.  For non-specific dyes, that is, dyes that do not 
exhibit cellular specificity, the blood and EES compartments may be sufficient to 
describe their distribution.95  However, for dyes that exhibit molecular specificity, a third 
compartment is included.  This third compartment represents the association of the dye 
at a molecular level, whether it is through surface receptor binding or cellular uptake.  
The rate at which the dye accumulates in the cellular compartment, whether through 
association with cellular membrane receptors or internalization, is denoted by R.
If the rate of accumulation of dye in the cellular compartment, R, is constant, 
determining the time-dependent dye concentration in each of the compartments is 
relatively straightforward.  However, in general, the association between the dye and the 










where, CEES is the concentration of the dye in the EES, Vm is the maximum rate of dye 
internalization or receptor association at the cellular compartment and Km is known as 
the Michaelis constant and is equivalent to the dye concentration at which the rate of 
uptake is equivalent to one-half the maximum rate.112  Eq. (6.1) is a form of the 
Michaelis-Menten expression for a saturable reaction based on a single substrate 
mechanism.112  Using Eq. (6.1) to express the rate of distribution of the dye to the 
cellular compartment leads to nonlinear pharmacokinetics and considerably complicates 
the mathematics of the model.  Fortunately, at low dye concentrations, where CEES is 
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where Vm/Km can be expressed as an apparent first-order rate constant, kc, that describes 
the distribution of dye between the EES and cellular compartments.  Furthermore, the 
distribution of dye from the EES to the cellular compartment is assumed to be a one-way 
process.  That is, cellular uptake is considered irreversible and dissociation of the 
receptor-dye complex is assumed to occur at a rate much slower than the rate of 
association.  Therefore, the rate constant for the reflux from the cell to the EES 
compartment is assumed to be negligible.  Applying this approximation, the diminution 
and accumulation of dye in each of the three compartments can be expressed as: 












where elpB kkk += , crEES kkk += , t is time, and CB, and CC represent the 
concentration of dye in the blood and the cell, respectively.  
The detected fluorescence intensity at the tissue surface is mediated by a number 
of factors including the tissue optical properties of scattering and absorption and the 
depth and concentration of the embedded fluorophore within the tissue.  For purposes of 
monitoring the temporal fluorescence intensity the optical properties of the tissue are 
assumed to be constant so that the detected fluorescence intensity may be expressed as a 
weighted sum of the concentration of the dye in each compartment:
( ) CEESB CwCwCwtI 321 ++≅ , (6.6)
where ( )tI  is the time-dependent fluorescence intensity and 1w , 2w , and 3w  are 
weighting functions that represent the volume fraction of the blood, EES, and the 
cellular compartments, respectively.  Additionally, the weighting functions account for 
the attenuation that occurs as the fluorescent light traverses each compartment.
To obtain the time-dependent dye concentration in each of the compartments, the
system of differential equations given by Eqs. (6.3), (6.4) and (6.5) may be solved 
simultaneously subject to the initial condition that at the time of i.v. bolus injection of 
the dye, 0=t , BoB CC = , 0=EESC , and 0=cC  (see Appendix B).  The results may 
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then be applied to Eq. (6.6) to obtain the following expression for the time-dependent 
observed fluorescence intensity:
( ) ( )[ ] ( )[ ]tBtAItI o βα −−+−−+= exp1exp1 (6.7)
where
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The pre-exponential factors A and B are concentration terms that mathematically 
reflect the magnitude of the detected signal.  Upon inspection of Eqs. (6.9) and (6.10) 
one observes that it is difficult to relate these parameters to physiologically relevant 
indications of disease such as the volume fractions of vascular and extravascular space 
or the rate constants governing dye uptake.  Nonetheless, these parameters may reflect 
high vascular volumes associated with diseases.95
An examination of Eq. (6.11) and (6.12) reveals that the complex rate constant α
must be greater than β.  As a result, at early time points the expression for the observed 
fluorescence intensity is more strongly influenced by the term containing α.  However, 
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the exponential term containing α approaches zero more rapidly than does the term 
containing β.  Consequently, at later time points the expression for the observed 
fluorescence intensity becomes a function of β alone.  Therefore, the early time portion 
of the fluorescence intensity profile is referred to as the α phase whereas the later 
portion is known as the β phase.
Furthermore, it is evident that the values of α and β are intimately related to the 
values of all other rate constants.  It is particularly interesting to examine how α and β
vary with the magnitude of the elimination rate constant, kel.  For example, if the value 
of kel is varied while all other rate constants remained fixed, the root function that 
appears in the expression for both α and β would asymptotically approach B EESk k−  for 
large values of kel and EES Bk k−  for small values.  As a result, α approaches kB while β
approaches kEES when the intrinsic elimination is very rapid.  The trend is reversed when 
elimination is slow; α approaches kEES while β approaches kB.  Finally, because α and β
differ by only the sign in front of the root function, the sum of α and β yields the sum of 
all rate constants between the various compartments of the model, 
el p r ck k k kα β+ = + + + .  One may exploit this result to determine the magnitude of the 
rate constant for specific uptake of contrast agent within the cellular compartment, kc as 
follows: for a given specific contrast agent administered in an animal bearing a tumor 
model in which the specific cellular uptake mechanism has been compromised while the 
remaining mechanisms of dye uptake remain unchanged, the net decrease in α β+
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reflects the magnitude of the rate constant for specific cellular uptake of the contrast 
agent.  
As a final note, from Eq. (6.7) it is evident that Io represents the fluorescence 
intensity at the time of contrast agent administration or background fluorescence 
intensity level.  Thus, when one applies a background subtraction technique, the 
mathematical equivalent of setting Io equal to zero, the number of parameters to be fit is 
reduced such that the time-dependent observed fluorescence intensity may be expressed 
as:
( ) ( ) ( )1 exp 1 expI t A t B tα β   = − − + − −    , (6.13)
where the pharmacokinetic parameters A, B, α, and β were previously defined in Eqs. 
(6.9), (6.10), (6.11), and (6.12).  Given time-dependent observations of fluorescence 
intensity, Eq. (6.13) may be employed in a regression algorithm to obtain estimates of 
the pharmacokinetic parameters A, B, α, and β.
6.3 Materials and Methods
6.3.1 Fluorescent Dyes and Animal Model
The monofunctional hydroxysuccinimide ester of Cy5.5 dye (Cy5.5-NHS, MW 1kD) 
was purchased from Amersham Biosciences (Piscataway, NJ) and conjugated to RGD 
peptide in-house at the M.D. Anderson Cancer Center by Dr. Wei Wang.  The free 
Cy5.5 dye was used as is after dilution in saline.
For the preparation of the animal models, four to six week-old female athymic 
nude mice (nu/nu; 18 –22 g) were purchased from Harlan Sprague Dawley, Inc. 
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(Indianapolis, IN).  Animals were maintained in a specific pathogen-free mouse colony 
in the Department of Veterinary Medicine (The University of Texas M. D. Anderson 
Cancer Center, Houston, TX).  The facility is accredited by the American Association 
for Laboratory Animal Care and all experiments were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee.
Human Kaposi’s sarcoma KS1767 tumor cells were implanted subcutaneously 
into the thigh region of mice.  All the tumor cell work, including preparation of the 
animal models, was performed by collaborators, primarily Dr. Shi Ke and Dr. QingPing 
Wu.  Mice were imaged when the tumor size reached approximately 2-mm in diameter.
Animals were subdivided into four test groups based on the contrast agent 
administered.  Animals in the first group received the free Cy5.5 dye, while animals in 
the remaining three groups were administered the RGD-Cy5.5 conjugate.  Of those 
animals receiving the conjugate dye, one-third received the conjugate dye alone; one-
third received the conjugate one hour after the intravenous injection of RGD peptide; 
and the remaining third received the conjugate 24-hrs after the intravenous injection of 
the RGD peptide. 
6.3.2 Instrumentation
Excitation light provided by a laser diode (660-nm, 35-mW; Sanyo, model, Allendale, 
NJ) was expanded via a plano-convex lens (ThorLabs, model , Newton, NJ) and a 
holographic diffuser (Edmund Industrial Optics, model NT54-494, Barrington, NJ) to 
provide a uniform excitation field of approximately 12-cm in diameter over the surface 
of the animal.  A laser diode driver (ThorLabs, model LDC500, Newton, NJ) provided 
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the diode with 60-mA of dc current while a temperature controller (ThorLabs, model 
TEC2000, Newton, NJ) helped maintain a constant lasing wavelength.
An intensified charge-coupled device (ICCD), comprised of a 16-bit CCD 
camera (Photometrics, model CH350/L, Tucson, AZ) coupled to an image intensifier
(model FS9910C, ITT Night Vision, Roanoke, VA) via a 105-mm lens, functioned as an 
area detector of re-emitted fluorescence light.  A whole-body fluorescence image of the 
animal, approximately 12-cm in diameter, was focused onto the photocathode of the 
image intensifier with a 50-mm lens.  A holographic notch-plus band rejection filter 
(660-nm center wavelength; Kaiser Optical Systems, Inc., Ann Arbor, MI) and a 
bandpass filter (710-nm center wavelength; CVI Laser, Albuquerque, NM) were 
positioned prior to the 50-mm lens to reject backscattered and reflected excitation light 
and isolate only re-emitted fluorescence light.  For the acquisition of white-light images, 
a low-power lamp provided a white-light source and the filters were removed.  Image
acquisition was controlled by a personal computer equipped with V++ imaging software 
(Digital Optics, Auckland, New Zealand). A schematic of the instrumentation is 
provided in Figure 6.2.
6.3.3 Experimental Method
Prior to the onset of the fluorescence imaging procedure, mice were anesthetized by 
intraperitoneal injection of 50-mg (kg bw)-1 Nembutal (Sigma, St. Louis, MO) and a 
catheter was positioned into the tail vein to facilitate the subsequent delivery of the 
fluorescent dye.  The anesthetized mouse was then positioned beneath the imaging 
system and image acquisition commenced.  Fluorescence images were obtained every 
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Figure 6.2.  Instrumentation for the intensified charge-coupled device (ICCD) 
small animal imaging system.
seven seconds for a period of approximately 18-minutes following the injection of 
contrast agent.  The first five images were acquired prior to the bolus administration of 
the fluorescent probe, and thus, served as baseline or background images.  The injected 
dose of RGD-Cy5.5 and the image exposure time were equivalent to 3-nmol (in 0.3-ml 
volume) and 800-msec, respectively, and were constant for all the imaging studies 
conducted.  Fluorescence images were obtained at 24-hrs post initial injection and again 
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every 24-hrs thereafter until little or no fluorescence signal was detectable from the 
tumor region of interest, as determined qualitatively, for up to 168-hrs.
6.3.4 Data Analysis
Upon completion of the imaging routine, a background image was subtracted from each 
of the acquired fluorescence images.  The white light image was then used to define two 
regions of interest (ROI); one was located entirely within the circumference of the tumor 
and the other, approximately equivalent in size, defined a region of normal tissue located 
symmetrically opposite the tumor site.  Utilizing Matlab software (The MathWorks, Inc., 
Natick, MA) the mean of the fluorescence intensity within each ROI was computed for 
every fluorescence image acquired.  Using this data, curves of mean fluorescence
intensity versus time were then generated for each of the imaging studies performed.  
The analytical expression for time -dependent fluorescence intensity, Eq. (6.13), was then 
fitted to the observed mean fluorescence intensity versus time data via a nonlinear 
Levenberg-Marquardt regression algorithm available in the SigmaPlot software package 
(SPSS Inc., Chicago, IL).  Estimates of the pharmacokinetic parameters A, B, α, and β
were obtained from the analysis for each curve.
6.4 Results and Discussion
The pharmacokinetic parameters A, B, α, and β were obtained from the nonlinear least 
squares analysis of the time-dependent fluorescence intensity data.  Figure 6.3 displays 
the results of the regression in a plot of the fluorescence intensity profile and the 
corresponding least-squares fit obtained from one representative animal of each of the 
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Figure 6.3.  Fluorescence intensity versus time profiles obtained from one 
representative animal of each of the groups that received an injection of the RDG-
Cy5.5 conjugate, acquired from the (a) tumor ROI and (b) normal ROI.  The 
symbols denote experimental measurements while the solid line denotes the 
corresponding least-squares fit.  The squares (□) denote data from an animal 
receiving the RGD-Cy5.5 conjugate alone, while the circles (○) and diamonds (◊) 
represent data obtained from an animal receiving the conjugate one hour and 24-
hours, respectively, after the injection of RGD peptide.
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groups that received an injection of the RDG-Cy5.5 conjugate.  Table 6.1 summarizes 
the results of such an analysis preformed on all experimental data obtained: two regions 
of interest (normal and tumor) investigated per each animal in one of four test groups as 
outlined in Section 6.3.2.  Table 6.1 reports estimates for the pharmacokinetic 
parameters A, B, α, and β and the value of α β+  with a 95% confidence interval on the 
estimate.  The coefficient of determination R2 for the regression was 0.99 or greater in all 
cases.
Furthermore, the mean value of the pre-exponential parameters A and B obtained 
from each of the test groups of animals investigated is presented in Figure 6.4.  An
examination of Figure 6.4 reveals that for the same type of ROI under investigation, the 
pre-exponential pharmacokinetic parameters A and B agree considerably well among 
animals that were injected with the RDG-Cy5.5 conjugate, while they are significantly 
lower for animals receiving the free Cy5.5 dye.  As discussed in Section 6.2 the pre-
exponential factors A and B reflect the magnitude of the detected signal and thus, are not 
only subject to the concentration of injected fluorophore but also will vary with 
experimental conditions such as detector sensitivity and excitation light fluence.  Thus, 
the fact that A and B are significantly different for animals that received the free Cy5.5
dye reflects the differences in signal intensities arising from the use of a different 
contrast agent, and may not truly reflect differences in pharmacokinetics.  On the other 
hand, because the exponential factors α and β are dictated by the shape of the 
fluorescence intensity profile rather than the magnitude of detected signal, they may be 
directly comparable between different experimental trials utilizing the same or different 
128
Table 6.1.  Results of the nonlinear regression of observed fluorescence intensity versus time data.  The pharmacokinetic 
parameters, as defined by Eq. (6.13), are reported with a 95% confidence interval on the estimate.  The table lists the results of 
data obtained from the distinct ROIs containing normal and tumor tissue for each of the four test groups investigated, as outlined 
in Section 6.3.1.
ROI contrast agent animal A (a.u.) B (a.u.) α × 101 (s-1) β × 103 (sec-1) α + β (sec-1)
097 14 ± 3 27 ± 4 0.35 ± 0.08 2.2 ± 0.4 0.037 ± 0.008Cy5.5
099 13 ± 2 26 ± 2 0.58 ± 0.09 1.9 ± 0.4 0.060 ± 0.009
355 245 ± 18 496 ± 7 0.63 ± 0.09 2.7 ± 0.2 0.066 ± 0.009
357 266 ± 26 479 ± 11 0.75 ± 0.09 3.2 ± 0.2 0.078 ± 0.009
RGD-Cy5.5
358 227 ± 13 320 ± 9 0.59 ± 0.07 1.7 ± 0.2 0.061 ± 0.007
356 228 ± 16 408 ± 6 0.66 ± 0.09 2.5 ± 0.2 0.069 ± 0.009
359 225 ± 12 284 ± 7 0.40 ± 0.04 3.2 ± 0.2 0.043 ± 0.009
RGD-Cy5.5
1-hr after RGD 
360 258 ± 19 346 ± 8 0.97 ± 0.09 3.3 ± 0.2 0.100 ± 0.009





24-hr after RGD 094 135 ± 7 411 ± 3 1.0 ± 0.1 2.2 ± 0.1 0.10 ± 0.01
097 13 ± 3 27 ± 2 0.58 ± 0.04 1.9 ± 0.4 0.060 ± 0.004Cy5.5
099 15 ± 2 31 ± 2 0.57 ± 0.08 1.7 ± 0.2 0.059 ± 0.008
355 355 ± 32 669 ± 11 2.5 ± 0.7 3.9 ± 0.2 0.25 ± 0.07
357 356 ± 40 961 ± 15 2.1 ± 0.7 2.2 ± 0.2 0.21 ± 0.07
RGD-Cy5.5
358 374 ± 45 651 ± 15 1.6 ± 0.4 2.7 ± 0.2 0.16 ± 0.04
356 277 ± 48 475 ± 33 0.16 ± 0.04 2.3 ± 0.4 0.018 ± 0.004
359 254 ± 16 379 ± 10 0.38 ± 0.05 3.1 ± 0.2 0.041 ± 0.005
RGD-Cy5.5
1-hr after RGD
360 241 ± 22 442 ± 9 0.75 ± 0.08 3.3 ± 0.2 0.078 ± 0.008





24-hr after RGD 094 169 ± 14 823 ± 22 1.9 ± 0.4 1.2 ± 0.1 0.19 ± 0.04
129
Figure 6.4.  Results of the non-linear least- squares regression in determining the 
pharmacokinetic pre-exponential factors (a) A and (b) B.  The column height 
represents the mean value of the test group listed along the abscissa while the error 
bars represent the standard deviation.  The time in parenthesis represents the time 
between injection of the RGD peptide and the RGD-Cy5.5 conjugate.
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contrast agents.  For this reason, the remainder of the discussion shall focus on the
differences among the intensity-independent parameters α and β.
As is evidenced from Figures 6.5 and 6.6, the pharmacokinetic parameters α and 
β and the sum α β+  do not appear to differ between the normal ROIs of all animal 
groups studied; a series of homoscedastic pooled t-tests confirmed that the mean 
estimates of α, β, and α β+  are not significantly different, at a 95% significance level, 
among the various groups of animals investigate.  Furthermore, statistical analysis 
confirms no variance in the parameter β, with a 95% level of significance, among data 
obtained from the tumor ROIs of the various groups of animals studied.  However, the 
parameter α and the deviates among data obtained from the tumor ROIs of the various
animal groups studied.  For animals injected with free Cy5.5 and animals pretreated with 
RGD peptide one hour prior to the injection of the RGD-Cy5.5 conjugate the value of 
α averaged 0.058-sec-1 and 0.043-sec-1, respectively; values that are statistically similar 
at 95% level of significance to each other and to the mean values of α determined from 
the normal ROIs.  Similar trends are observed for the sum α β+ .  These results suggest 
that the free Cy5.5 dye exhibits similar pharmacokinetics in Kaposi’s sarcoma tumor 
tissue and in normal tissue.  Likewise, the conjugate RGD-Cy5.5 dye exhibits similar
pharmacokinetics in tumor and normal tissue when the administration of the dye is 
preceded by the injection of RGD peptide by one hour.
On the other hand, the parameter α averages 0.21-sec-1 and 0.17-sec-1 for data
obtained from the tumor ROIs in animals that received the RGD-Cy5.5 conjugate alone 
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Figure 6.5.  Results of the non-linear least- squares regression in determining the 
pharmacokinetic complex rate constants (a) α and (b) β.  The column height 
represents the mean value of the test group listed along the abscissa while the error 
bars represent the standard deviation.  The time in parenthesis represents the time 
between injection of the RGD peptide and the RGD-Cy5.5 conjugate.
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Figure 6.6.  Results of the non-linear least- squares regression in determining the 
sum of the pharmacokinetic complex rate constants βα + .  The column height 
represents the mean value of the test group listed along the abscissa while the error 
bars represent the standard deviation.  The time in parenthesis represents the time 
between injection of the RGD peptide and the RGD-Cy5.5 conjugate.
or the conjugate preceded by the injection of the RGD-peptide 24-hours earlier, 
respectively.  Statistical analysis revealed that while these values are statistically similar 
to each other at a 95% significance level they are in fact different from the values of the 
remaining test groups.  Thus, the value of α is on average an order of magnitude greater 
from within the tumor ROI of these two test groups of animals as it is from the tumor 
ROIs of animals in the remaining groups or the normal ROIs of animals in all groups.  
The sum α β+  exhibits the same trend.  These results suggest that pharmacokinetic 
differences between Kaposi’s sarcoma and normal tissue are reflected in the value of the 
parameter α and the sum α β+  when the conjugate RGD-Cy5.5 dye is employed alone 
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or 24-hours following the injection of the RGD peptide.  The impact of injection of the 
RGD peptide prior to the injection of the conjugate dye and the corresponding change in 
the parameter α is seen graphically in Figure 6.3 in the α−phase or the early part of the 
fluorescence intensity profiles.
From the studies involving the administration of the RGD peptide prior to the 
administration of the RGD-Cy5.5 conjugate one may draw the following conclusions.  
First, because the net effect of administering the RGD peptide one hour prior to the 
RGD-Cy5.5 conjugate is the reduction of the tumor uptake of the dye, as evidenced by 
the reduction of the parameter α from a mean value of 0.21-sec-1 (for animals injected 
with the RGD-Cy5.5 conjugate alone) to 0.043-sec-1 (for animals pretreated with the 
RGD peptide one hour prior to the administration of the RGD-Cy5.5 conjugate), and 
since the αvβ3 integrin receptor overexpressed on Kaposi’s sarcoma is known to bind the 
RGD peptide, the pharmacokinetic analyses verify the specific binding of the 
RGD-Cy5.5 conjugate to the Kaposi’s sarcoma tumor model.  Second, because the value 
of α obtained from the tumor ROIs of animals injected with the conjugate dye alone or 
the conjugate dye 24-hours following the pretreatment with the RGD peptide are 
statistically similar, one may speculate that the turnover of the αvβ3 integrin receptor 
expressed on the cell surface of Kaposi’s sarcoma occurs within 24-hrs.  Given 
experimental dynamic in vivo fluorescence data obtained subsequent to the injection of 
the RGD-Cy5.5 conjugate at various intervals following the administration of the RGD 
peptide, one may be able to experimentally determine receptor turnover time using a 
pharmacokinetic analysis.  Finally, since α β+  is equivalent to the sum of all the rate 
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constants of the compartmental pharmacokinetic model, and since the αvβ3 integrin 
receptors bind the RGD peptide such that the rate constant for cellular uptake of the dye 
conjugate becomes essentially zero, 0ck = , the difference in the value of α β+  between 
animals injected with the conjugate dye alone and animals injected with the conjugate 
one hour after the pretreatment with the RGD peptide reflects the value of the rate 
constant for specific cellular uptake of the conjugate kc.  Thus, the value of rate constant 
for the specific cellular uptake of the RDG-Cy5.5 conjugate was found to have a mean 
value of 10.16 secck
−= .
Fluorescence images of all animals studied were also obtained at 24-hour 
intervals following the administration of the contrast agent.  Figure 6.7 displays the
images of raw fluorescence (i.e. no background subtraction) obtained 24-hours and 
48-hours following the initial injection of the contrast agent for a representative animal 
of each of the four test groups studied.  The fluorescence images overlay white light 
images to allow for visualization of the entire animal and are plotted on the same linear 
scale to allow for a direct quantitative comparison of the images.  From the images of 
Figure 6.7(a) it is clear that the Kaposi’s sarcoma tumor was not visible from the 
fluorescence images at any time following the injection of the free Cy5.5 dye.  In this 
case and the other cases as well, the visible fluorescence intensity originating from the 
animal gut is due to animal diet.  The Kaposi’s sarcoma tumor was clearly visible 
24-hours and 48-hours after the administration of the RGD-Cy5.5 peptide, as evidenced 
in Figures 6.7(b-d), and returned to baseline after about 168-hours.  At any given time, 
the fluorescence intensity originating from the tumor was highest for the animal that was 
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Figure 6.7.  Raw fluorescence images (no background subtraction) obtained 
24-hours (1st column) and 48-hours (2nd column) after the administration of (a) 
Cy5.5, (b) RGD-Cy5.5 conjugate alone, (c) RGD-Cy5.5 conjugate 1-hour after the 
injection of RGD peptide, and (d) RGD-Cy5.5 conjugate 24-hours after injection 
of the RGD peptide.  The fluorescence images overlay white light images to 
clearly outline the animal.  The white arrows indicate the location of the 
xenografted Kaposi’s sarcoma tumor.
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administered the RGD-Cy5.5 conjugate alone, Figure 6.7(b); slightly diminished for the 
animal injected with the RGD peptide 24-hours prior to the administration of the 
conjugate dye, Figure 6.7(d); and lower still for the animal that received the RGD 
peptide one hour prior to the administration of the RGD-Cy5.5 conjugate, Figure 6.7(c).  
These results further substantiate the specific cellular binding of the RGD-Cy5.5 
conjugate to Kaposi’s sarcoma. 
6.5 Conclusion
Herein the use of a pharmacokinetic analysis on in vivo fluorescence data to test for the 
specificity of a targeted diagnostic fluorescence contrast agent in a murine Kaposi’s 
sarcoma model has been demonstrated.  The contrast agent, a peptide-cyanine dye 
conjugate termed RGD-Cy5.5, is targeted to αvβ3 integrin receptors commonly 
overexpressed on angiogenic epithelium.  Dynamic fluorescence images obtained 
immediately subsequent to the intravenous injection of the conjugate dye and a three-
compartment pharmacokinetic model were employed to estimate the rate constant for the 
cellular uptake of the dye in Kaposi’s sarcoma tumor tissue.  The rate constant was 
found to have a value of 0.16-sec-1.  Finally, based on the experiments employing the 
RGD peptide to block or internalize the target αvβ3 integrin receptors, one may speculate 
that the integrin receptor turnover occurs approximately within 24-hrs.
With targeted therapeutics becoming more common alternatives for the treatment 
of cancer, there exists a need for a reliable technique capable of assessing the efficacy of 
selected targeting schema.  While current methodologies employ in vitro assays, an in 
vivo technique may be extremely valuable to help establish specific membrane receptors 
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as bona fide targets for diagnostics and therapeutics.  The pharmacokinetic analysis 
developed in this report may provide one such in vivo technique.  Finally, the results 
demonstrate that utilizing a relatively simple mathematical model it may be possible to 
estimate receptor-ligand specificity, receptor expression level, and receptor turnover rate, 
all of which are important indicators of a targeting scheme’s utility. 
138
7. IMAGING OF EPIDERMAL GROWTH FACTOR RECEPTOR†
In addition to using pharmacokinetic analysis to evaluate novel targeting fluorescent 
contrast agents, simple continuous wave fluorescence imaging may be used to evaluate 
novel contrast agents.  In this section, CW fluorescence imaging is used to image human 
breast cancer xenografts following intravenous administration of an epidermal growth 
factor receptor-targeted fluorescent contrast agent.  As in the previous section, the work 
herein represents the collaborative effort with researchers at M.D. Anderson Cancer 
Center who developed the contrast agents and animal models.
7.1 Introduction
Non-invasive optical imaging may soon play a critical role in the early diagnosis of 
disease, the monitoring of early therapeutic response to treatment regimens, and the 
design of individually tailored therapy for enhanced efficacy.  With near-infrared (NIR) 
optical imaging comes the promise of an inexpensive, highly sensitive, and non-ionizing 
imaging modality capable of dynamic, real-time in vivo images.  Additionally, with the 
versatility of fluorescent probe design that is only now starting to become realized, 
optically based molecular imaging techniques are becoming more attractive.
Prior work in the design of specific fluorescent probes has established the use of 
antibody-directed targeting of NIR fluorescent probes21,23-25 as well as fluorophores 
† Reprinted in part with permission from “In vivo fluorescence imaging of cyanine derivative modified 
with epidermal growth factor EGF-Cy5.5 in a murine model of carcinogenesis” by M. Gurfinkel, S. Ke, C. 
Li, and E.M. Sevick-Muraca, 2003.  Proceeding of the SPIE: Genetically Engineered and Optical Probes 
for Biomedical Applications 4967, 108-116.  Copyright 2003 by the International Society for Optical 
Engineering.
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conjugated with polymers for fluorescent activation by metalloproteases35 and 
intracellular enzymes33,34 present in cancer.  However, adverse immunogenic reactions 
were often observed with antibody-directed targeting26 and, for the detection of solid 
tumors, the penetration of large antibodies and polymeric complexes may be impeded by 
pressure gradients within the tumor.29  Alternatively, small peptide conjugation to 
fluorophores has been demonstrated in vivo to target somatostatin,27,28,30 bombesin,27,28,30
and transferrin31 receptor-rich tumors, as well as hydroxyapatite for the monitoring of 
osteoblastic activity.32
In this section, the use of a novel receptor-targeted NIR fluorescent probe is 
described and its specific targeting of human breast cancer xenografts is demonstrated in 
a small animal model.  An ICCD detection system is employed to acquire whole-body 
fluorescence images immediately following the intravenous administration of the 
fluorescence probe, as well as fluorescence data at later time points, both of which are 
used to validate the specificity of the probe for the cancer target.
7.2 Materials and Methods
7.2.1 Fluorescent Dyes and Animal Model
For this study, the fluorescent contrast agents and animal models were developed at the 
M.D. Anderson Cancer Center by Dr. Xiaxia Wen, and Dr. Shi Ke and Dr. QingPing Wu, 
respectively.  For the synthesis of the epidermal growth factor receptor (EGFr)-targeted 
fluorescent dye, a quantity of 0.2-mg of human recombinant epidermal growth factor 
(EGF) (MW 6kD; Sigma, St. Louis, MO) was labeled by incubation with four 
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equivalents of the monofunctional hydroxysuccinimide ester of Cy5.5 dye (MW 1kD; 
Amersham Pharmacia Biotech Inc., Piscataway, NJ).  The resulting fluorescent probe, 
termed EGF-Cy5.5, was composed of one molecule of EGF for every two Cy5.5 
molecules (molar ratio 1:2) as determined by MALDI-MS.  Indocyanine green (ICG) 
(Sigma) and C225 antibody (ImClone Systems Inc., New York, NY) were used as 
received from the manufacturer.
Four to six week-old female athymic nude mice (nu/nu, 18-22-g) (Harlan 
Sprague Dawley, Inc., Indianapolis, IN) were housed five per cage and fed a diet of 
sterilized chow and water ad libitum.  Animals were kept in a pathogen-free mouse 
colony in the Department of Veterinary Medicine (The University of Texas M.D. 
Anderson Cancer Center).  The facility is accredited by the American Association for 
Laboratory Animal Care and all experiments were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee.
Human breast adenocarcinoma cell lines MDA-MB-435 and MDA-MB-468 
(American Type Culture Collection, Rockville, MD) were maintained in Dulbecco's 
Modified Eagle's Medium / Nutrient Mixture F-12 Ham (DMEM/F12) and 10% fetal 
bovine serum (FBS) (Gibco, Grand Island, NY) in a humidified atmosphere of 5% CO2
at 37°C.  Cells were pelleted by centrifugation and resuspended in sterile PBS.  Each 
nude mouse was injected with the adenocarcinoma cells (2-3 × 106 cells) subcutaneously 
into the chest region.  Fluorescence imaging of the mice took place once the tumors 
reached approximately 6-mm in size.
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7.2.2 Imaging System
The small animal imaging system was comprised of (i) a laser diode source of excitation 
photons; (ii) an intensified charge-coupled device camera (ICCD) detection system; and 
(iii) a personal computer for data acquisition and storage.  The laser diode source 
(785-nm, 80-mW for ICG; 660-nm, 35-mW for Cy5.5) was expanded to approximately 
8-cm diameter using a plano-convex lens to provide an excitation source over nearly the 
entire animal.  The detection system consisted of an image intensifier (model FS9910C, 
ITT Night Vision, Roanoke, VA) lens-coupled to a 16-bit CCD camera (model CH350, 
Photometrics, Tucson, AZ).  The system was designed such that the field of view could 
be varied from 3 × 3-cm to over 12 × 12-cm by varying the image distance of the 50-mm 
lens used to focus the image onto the photocathode of the intensifier.  Such a design 
permits zoom capabilities without resorting to moving either the camera above the 
animal or the anesthetized animal itself.  The lens was fitted with a holographic notch-
plus band-rejection filter (785-nm center wavelength for ICG, 660-nm center wavelength 
for Cy5.5; Kaiser Optical Systems, Inc., Ann Arbor, MI) and a bandpass filter (830-nm 
center wavelength for ICG, 710-nm center wavelength for Cy5.5; CVI Laser 
Corporation, Albuquerque, NM) to reject back-scattered and reflected excitation photons 
and isolate fluorescent photons.  For the acquisition of white-light images, a low-power 
lamp provided a white-light source and the filters were removed.  Image acquisition was 
directed by V++ software (Digital Optics, Auckland, New Zealand) while data 




Mice were anaesthetized (Nembutal, Sigma; 50-mg/kg administered i.p.) and positioned 
beneath the imaging system.  The image acquisition time was held constant at 800-ms 
while intensifier gain was varied from 40% of the maximum gain (for white light images) 
to 95% of the maximum gain (for fluorescence images).  The mice were then injected 
via tail vein with either ICG (0.3-mL, 890-picomoles), Cy5.5 dye alone (0.3-mL, 
17-nanomoles), or EGF-Cy5.5 conjugate (0.3-mL, 17-nanomoles equivalent Cy5.5).  
Fluorescence images were obtained every six seconds for a period of approximately 
20-minutes following initial injection of contrast agent, and again every 24-hours 
thereafter until very little or no fluorescent signal was detectable from the tumor region 
of interest (as determined qualitatively) for up to 192-hours.
7.3 Results and Discussion
Images of endogenous fluorescence at 830-nm and 710-nm (emission wavelengths of 
ICG and Cy5.5, respectively) revealed no endogenous fluorophores at 830-nm while 
some extent of endogenous fluorescence was observed to originate from the intestines at 
710-nm.  Experiments later confirmed that the endogenous signal at this wavelength was 
primarily a result of the animals’ diet.  Nonetheless, the location of the tumor in the 
chest region of the animal enabled the discrimination of fluorescent signal emanating 
from tumor from that emanating from endogenous abdominal sources.
The use of an intensified CCD detection system not only allows for the detection 
of small quantities of fluorescent dye, but it enables the use of sub-second exposure 
times which, in turn, permits the rapid acquisition of fluorescence data.  As a result, 
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starting at the time of injection, the circulation of fluorophore may be followed 
throughout the body in real time and thus, biodistribution and pharmacokinetic studies 
may be performed for early time points.  Figure 7.1 illustrates the mean fluorescence 
intensity as a function of time (the initial twenty minutes following injection of agent) 
from the ROIs defining tumor and normal tissues for all tumor models and contrast 
agents studied.  Regardless of tumor type, there is little difference in the 
pharmacokinetics when a non-specific agent is employed [Figs. 7.1(a), 7.1(c) , 7.1(d)] or 
when the EGFr specific EGF-Cy5.5 dye is employed in an EGFr-negative tumor model 
[Fig. 7.1(b)].  Furthermore, the greatest disparity in pharmacokinetics between normal 
and tumor ROIs occurs for EGF-Cy5.5 in an EGFr-positive, tumor-bearing mouse [Fig. 
7.1(f)].  Pretreatment of an EGFr-positive, tumor-bearing mouse with C225 antibody 
dramatically reduces this difference in pharmacokinetics [Fig. 7.1(e)].  Taken together, 
these results suggest that the difference in pharmacokinetics is a result of the specific 
binding of EGF-Cy5.5 to EGFr in MDA-MB-468 tumor cells.
Figure 7.2 presents fluorescence images in pseudocolor obtained 24- and 
48-hours after the injection of EGF-Cy5.5 into an EGFr-negative, MDA-MB-435 tumor-
bearing mouse.  The figure illustrates that there is little accumulation of EGF-Cy5.5 in 
the MDA-MB-435 tumor 24-hours post injection (tumor fluorescence is approximately 
20 percent of the maximum signal).  At 48-hours post injection, tumor fluorescence is
still weaker, with the signal slightly above background fluorescence.  On the other hand,
Figure 7.3 depicts the fluorescence images obtained after the injection of EGF-Cy5.5 
into an EGFr-positive, MDA-MB-468 tumor-bearing mouse.  Unlike the previous case,  
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Figure 7.1.  Fluorescent intensity as a function of time after injection of (a) Cy5.5 
in an MDA-MB-435 tumor-bearing mouse, (b) EGF-Cy5.5 in an MDA-MB-435 
tumor-bearing mouse, (c) ICG in an MDA- MB-468 tumor-bearing mouse, (d) 
Cy5.5 in an MDA-MB-468 tumor-bearing mouse, (e) EGF-Cy5.5 in an MDA-
MB-468 tumor-bearing mouse pretreated with C225 antibody 24 hours earlier, and 
(f) EGF-Cy5.5 in an MDA-MB-468 tumor-bearing mouse.
the tumor fluorescence signal is appreciable after 24-hours and is greatest after 96-hours, 
at which time it is approximately seventy percent of the maximum signal.  It is not until 
192-hours post-injection when the tumor fluorescence signal drops below twenty percent 
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Figure 7.2.  Pseudocolor fluorescence images of a tumor-bearing (MDA-MB-435) 
mouse collected 24 and 48-hrs following injection of EGF-Cy5.5.  Regions of high 
fluorescence intensity appear dark red.  The obtained fluorescence images overlay 
a white light image to permit registration of the fluorescence signal and 
visualization of the entire animal.
Figure 7.3.  Pseudocolor fluorescence images of a tumor-bearing (MDA-MB-468) 
mouse collected 24, 96 and 192-hrs following injection of EGF-Cy5.5.  Regions of 
high fluorescence intensity appear dark red.  The obtained fluorescence images 
overlay a white light image to permit registration of the fluorescence signal and 
visualization of the entire animal.
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of the maximum detected signal.  Figure 7.4 illustrates the fluorescence images obtained 
from an EGFr positive, MDA-MB-468 tumor-bearing mouse pretreated with C225 
antibody 24-hours prior to injection of EGF-Cy5.5.  No significant tumor fluorescence is 
observed at 24-hours post-injection and tumor fluorescence is indistinguishable from 
background signal at 48-hours.  The images suggest that pretreatment with C225 
antibody prevents EGF-Cy5.5 accumulation in the tumor, further substantiating the 
claim that EGF-Cy5.5 binds EGFr in vivo in MDA-MB-468 tumor.
Figure 7.4.  Pseudocolor fluorescence images of a tumor-bearing (MDA-MB-468) 
mouse collected 24 and 48 hours following injection of EGF-Cy5.5.  The 
EGF-Cy5.5 injection was preceded by the administration of C225 antibody 
24-hours earlier.  Regions of high fluorescence intensity appear dark red.  The 
obtained fluorescence images overlay a white light image to permit registration of 
the fluorescence signal and visualization of the entire animal.
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7.4 Conclusion
The results of the work in this section demonstrate that simple fluorescence imaging may 
be used to visualize the fluorescence resulting from tumor laden fluorophores.  
Furthermore, the results demonstrate that the specific fluorescent contrast agent, 
EGF-Cy5.5, can be used to discriminate EGFr-expressing tumor from non-tumor tissue 
based on preferential accumulation of the agent in the tumor.  Furthermore, the results 
indicate that the non-specific contrast agents ICG and Cy5.5 show no preferential 
accumulation in either the EGFr-negative MDA-MB-435 or EGFr-positive 
MDA-MB-468 tumor-bearing mice.  Negligible tumor fluorescence was detected 
24-hours after dye administration in each case.  Furthermore, the EGF-Cy5.5 conjugate 
displayed specificity only for MDA-MB-468 tumors but not for MDA-MB-435 tumors.  
Tumor fluorescence reached a maximum after 96-hours in the MDA-MB-468 tumor and 
only dropped to insignificant levels after 192-hours.
Additionally, the initial pharmacokinetics following dye administration may be
used to reflect the differences in specificity of the dye.  Both ICG and Cy5.5 show no 
difference between tumor and non-tumor pharmacokinetics regardless of tumor EGFr 
expression level.  EGF-Cy5.5 demonstrates no differential pharmacokinetics between 
tumor and non-tumor tissue for the EGFr-negative MDA-MB-435 tumor-bearing mouse 
whereas, the greatest observed difference in pharmacokinetics between tumor and non-
tumor tissue occurs for EGF-Cy5.5 in the EGFr-positive MDA-MB-468 tumor-bearing 
mouse.  These findings suggest that specific or targeted contrast agents may be used 
more effectively for the diagnosis of solid tumors.
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8. PRELIMINARY STUDIES
In additional to the complete animal imaging studies presented in Sections 5–7, the 
developed optical imaging instrumentation has been utilized to investigate a number of 
additional novel contrast agents, developed by researchers at M.D. Anderson Cancer 
Center (MDACC) under the direction of Dr. Chun Li, for the detection of carcinogenesis 
in vivo.  This section describes preliminary results from a number of ongoing clinical 
investigations.
8.1 Imaging Carcinogenesis in Small Animals
In addition to the fluorescent contrast agents developed to target low-density lipoprotein 
(LDL) receptors (Section 5), αvβ3 integrin receptors (Section 6), and epidermal growth 
factor receptors (EGFr) (Section 7), a number of novel chemical constructs have been 
developed for consideration as delivery vehicles for optical contrast agents.  Among 
them is a conjugate of the cyanine dye, Cy5.5, synthesized at MDACC by Dr. Wei Wang 
to specifically target matrix-metalloprotease (MMP), an enzyme whose presence and 
strong upregulation in many cancers, including human prostate cancer, has been noted
and shown to promote metastatis.113-115
An additional contrast agent under investigation, synthesized at MDACC by Dr. 
Xianyi Cao, is a conjugate comprised of the fluorophore indocyanine green (ICG) bound 
to a poly-L-glutamic acid polymer.  Although its molecular targeting mechanism 
remains uncertain at this time, the conjugate has shown specificity towards bone and the 
skeletal system.  Furthermore, the poly-L-glutamic polymer construct allows the 
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additional conjugation of a nuclear radiolabel, 111In, and thus permits dual imaging 
capabilities and initial comparisons of optical imaging and nuclear imaging technology 
using the same contrast agent.
Finally, consider the following comparison of the commonly-used nuclear 
radiolabel 111In and optical probe ICG.  111In has a typical specific activity of 
161.55 10 emissions sec g× .116  The fluorophore ICG exhibits a mean lifetime of 
0.56 nsec  and has a molecular weight of 775 g mol .14  Because each molecule can 
repeatedly re-emit fluorescent photons, the mean lifetime and molecular weight combine
to yield an ‘optical’ specific activity for ICG of 301.39 10 emissions sec g× .  Thus, it 
requires approximately 139 10×  times more mass of 111In to yield the same number of 
radiative emissions per unit time as ICG.  This analysis represents a theoretical upper 
limit to the number of radiative events potentially available for detection.  While it does 
not consider radioactive decay, fluorescence quenching, detector collection efficiencies, 
quantum efficiency of fluorophore, and the availability of excitation source, it still 
makes a clear argument that optical imaging with fluorescent contrast agents may be
superior to nuclear imaging when it comes to the required concentration of contrast 
agent.  Certainly the other factors may mitigate this large difference in required contrast 
agent dose.  But given this argument, it is clear why optical imaging using fluorescent 
contrast agents is the topic of so many scientific inquiries.
An additional distinct advantage near-infrared fluorescence imaging possesses 
over conventional nuclear imaging is the ability to simultaneously image multiple 
contrast agents.  Because nuclear scintillation counters cannot distinguish the source of 
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the gamma emitter, they are incapable of discriminating between multiple radiolabels.  
However, because fluorescent contrast agents may exhibit different excitation and 
emission spectra, an optical detector capable of differentiating different wavelengths has 
the capacity to measure fluorescent emissions from multiple fluorescent probes. As 
discussed below, this feature of fluorescence imaging can further be exploited if time-
resolved measurements are made to capture information pertaining to the fluorescence 
decay kinetics of the fluorophore.
Simultaneous imaging of two probes was demonstrated in a preliminary study of 
a murine model of prostate cancer; a study conducted at MDACC in collaboration with 
Dr. Chun Li and colleagues.  Prior to imaging, human prostate cancer was xenografted
into the nude mouse via an intra-tibial injection and the resulting tumor mass was 
allowed to grow to approximately 5-mm in size.   The nude mouse was then tail-vein 
injected with 10-nmol of the ICG-poly-L-glutamic acid polymer conjugate and 15-nmol 
of the Cy5.5 probe conjugated to target MMP, and imaged 24-hrs later using the small 
animal ICCD detection system described in Section 3.  The sufficient separation of the 
fluorescence spectra between ICG and Cy5.5 (peak fluorescent emission occurs at 
~810-nm and ~710-nm, respectively) permits the simultaneous fluorescence imaging and 
coregistration of the two fluorescent probes.  Figure 8.1 presents the fluorescence images 
of both fluorescent probes obtained after the mouse was sacrificed and the skin removed 
to improve visualization of underlying structures.  Figure 8.1(a) is a pseudocolor 
fluorescence image of the ICG conjugate dye.  The individual vertebrate of the tail and 
the bones of the legs are clearly visible.  Figure 8.1(b) is a pseudocolor fluorescence 
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Figure 8.1.  Pseudocolor fluorescence images of (a) ICG-poly-L-glutamic acid 
polymer conjugate, and (b) Cy5.5 conjugate targeted to MMP obtained 24-hrs 
following the intravenous administration of the said fluorescent probes in a 
prostate cancer bearing nude mouse.  The white arrow indicates the location of the 
prostate cancer tumor.  Panel (c) is a composite image of the images in panels (a) 
and (b) where the ICG conjugate fluorescence is pseudocolored green while the 
Cy5.5 conjugate fluorescence is pseudocolored red.
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image of the Cy5.5 conjugate dye.  The white arrow indicates the location of the prostate 
cancer tumor which is clearly visible due to Cy5.5 fluorescence.  Figure 8.1(c) is a 
composite pseudocolor fluorescence image of both conjugate dyes (ICG conjugate is 
pseudocolored green; Cy5.5 conjugate dye is pseudocolored red).  In the composite 
image, the location of the prostate cancer tumor is clearly observed to coincide with the 
initial intra-tibial implantation.
8.2 Small Animal Frequency-Domain Photon Migration Imaging
Initial attempts to acquire frequency-domain photon migration images of tumor 
fluorescence in vivo were also conducted.  Although FDPM is unnecessary to visualize 
fluorescence from very shallow tissue depths and small volumes such as the small 
animals utilized in the experiments, it is necessary for the tomographic three-
dimensional recovery of tumor size and location in larger volumes more relevant to 
clinical imaging of larger subjects including humans.39-41,117  Previous tests 
havevalidated the instrumentation for the acquisition of frequency-domain data from 
tissue-simulating phantoms (Section 4).  To validate the instrument for the acquisition of
FDPM data from fluorescence-laden tumors in small animal models, a number of 
preliminary experiments were conducted.
In addition to the continuous-wave imaging studies described in the previous 
section, a small animal model of breast carcinoma was imaged using FDPM techniques.  
The ICCD imaging system used to obtain the FDPM data is described in detail in 
Section 3.  Four phase-sensitive fluorescence intensity images were acquired at sixteen
equally spaced phase-delays between the frequency synthesizers modulating the 
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excitation source and the intensifier detector.  Unless otherwise noted, all FDPM studies 
were conducted at an RF-modulation frequency of 100-MHz.  The phase and RF-
amplitude of the emitted fluorescence photon density wave was then computed at each 
pixel of the CCD array via a fast Fourier transform (FFT) of the mean of the phase-
sensitive intensity data.60
Figure 8.2 shows the results of the frequency-domain imaging experiment 
performed on an MDA-MB-468 tumor-bearing mouse 96-hours following injection of 
EGF-Cy5.5.  In order to achieve desirable modulation depth, the intensifier cathode 
voltage was reduced by 70% and the diameter of the expanded excitation source was 
decreased to approximately 6-cm.  These experimental changes could explain why the 
DC image shows reduced tumor contrast compared to the CW images of the same 
animal (compare to Figure 7.3).  Nonetheless, the tumor is clearly evident in the image 
of AC amplitude.  Furthermore, comparing the normalized DC and AC intensities along
the same horizontal slice through the image reveals that the normalized AC intensity is 
consistently greater than the DC intensity.  This is due in part to the inherent ability of 
the frequency-domain technique to filter out non-modulated ambient light which may 
contribute to noise in CW imaging.
Although the FDPM images of phase-lag have been omitted from this initial 
experiment, they can be used to impart additional contrast, especially when a 
fluorophore designed to exhibit lifetime-sensitivity to its local biochemical environment 
is employed.
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Figure 8.2.  White light and frequency-domain images of DC and AC amplitude of 
a tumor-bearing (MDA-MB-468) mouse collected 96 hours following injection of 
EGF-Cy5.5.  The normalized DC and AC intensity at each pixel on the line 
through the tumor region (shown in white) are also plotted.
To demonstrate the ICCD detection system’s capacity to detect phase lag in 
FDPM imaging experiments, an experiment was conducted in which a prostate cancer 
tumor-bearing mouse was imaged with the two contrast agents described in the previous 
155
section, that is, ICG-poly-L-glutamic acid polymer conjugate to target bone and the 
Cy5.5 conjugate to target MMP expression in the prostate cancer tumor.
FDPM imaging was conducted 24-hours following the intravenous 
administration of both contrast agents.  Two FDPM experiments were conducted, one to 
image the fluorescence from each of the fluorescent probes.  Again, the sufficient 
separation of the fluorescence emissions of the two fluorophores permits simultaneous 
imaging of both agents.  Excitation light was delivered via an expanded laser diode 
source (660-nm for Cy5.5, 785-nm for ICG) and optical filters were used to isolate the 
emission wavelength of interest.  In order to improve the modulation of the excitation 
source, and thus, the results of the FDPM imaging experiments, the expanded source 
was focused primarily over the region of the animal’s leg containing the implanted 
prostate cancer tumor.  Four phase-sensitive fluorescence intensity images were obtained 
at sixteen equally spaced phase-delays between the frequency synthesizers modulating 
the excitation source and the intensifier detector.  The mean of the phase-sensitive 
fluorescence images at each phase delay was used in the FFT algorithm to compute the 
modulation amplitude and the phase-lag.60
Figure 8.3 shows the phase-lag images obtained from the experiments.  Figure 
8.3(a) is the phase-lag image obtained after imaging the fluorescence from the MMP-
targeted Cy5.5 conjugate dye; Figure 8.3(b) is the phase-lag image obtained from the
fluorescence images of the bone-targeted ICG-poly-L-glutamic acid polymer conjugate.  
Because the expanded excitation light was focused over the region of the leg containing 
the tumor, the phase contrast in distant regions of the animal is poor.  Nonetheless, in 
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Figure 8.3(a) it appears that the tumor is delineated by the phase-contrast due to the 
Cy5.5 conjugate dye.  It is difficult to discriminate any structures from the phase contrast 
due to the ICG polymer conjugate [Figure 8.3(b)] perhaps because ICG-polymer 
conjugate is located throughout the bones in the leg.
In addition to phase-lag images, the FDPM imaging study yielded images of DC 
and AC amplitude, and modulation depth (DC/AC).  Figure 8.4 displays the FDPM 
results of the fluorescence imaging study conducted on the Cy5.5 conjugate dye. Figure 
8.4(a) is a white light image, and Figures 8.4(b), 8.4(c), 8.4(d) are FDPM images of DC 
amplitude, AC amplitude, and modulation depth (DC/AC), respectively.  The images of 
DC and AC amplitude clearly delineate the location of the prostate cancer tumor while 
the image of modulation depth primarily mirrors the region of the expanded excitation
Figure 8.3.  Phase-lag images obtained from FDPM imaging studies of (a) Cy5.5 
conjugate targeted to MMP in prostate cancer and (b) bone-targeted ICG-polymer 
conjugate.  The arrow indicates the location of the prostate cancer tumor and the 
scale is in units of degrees.
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Figure 8.4.  Results of the FDPM fluorescence imaging experiment conducted on a 
prostate cancer tumor-bearing mouse 24-hrs following the administration of a 
Cy5.5 conjugate dye targeted to MMP in prostate cancer.  Panel (a) is a white light 
image, (b) DC amplitude, (c) AC amplitude, and (d) modulation depth.
light source.  Similarly, Figure 8.5 displays the results of the FDPM imaging study on 
the ICG-polymer conjugate dye.  Figure 8.5(a) is a white light image, and Figures 8.5(b), 
8.5(c), 8.5(d) are FDPM images of DC amplitude, AC amplitude, and modulation depth 
(DC/AC), respectively.  The images of DC and AC amplitude seem to highlight the 
patella and a portion of the tibia.  When the images in Figures 8.4 and 8.5 are 
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Figure 8.5.  Results of the FDPM fluorescence imaging experiment conducted on a 
prostate cancer tumor-bearing mouse 24-hrs following the administration of a 
bone-targeting ICG-polymer conjugate dye.  Panel (a) is a white light image, (b) 
DC amplitude, (c) AC amplitude, and (d) modulation depth.
coregistered, the regions of strongest fluorescence signal are displaced with respect to 
each other, indicating that the fluorescence dyes, do indeed target different locations.  
The preliminary FDPM images indicate that there certainly exists room for 
improvement and a need to optimize the experimental protocol for the acquisition of 
frequency-domain data in order to improve contrast, especially in the images of phase-
lag.  Nonetheless, the results of this section demonstrate that a frequency-domain 
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imaging technique can be used to efficiently image fluorescence laden tumors in small 
animals.  In addition to providing a method to reject ambient light, frequency-domain 
imaging provides a convenient way to extract temporal information vis-à-vis fluorophore 
decay kinetics.  Finally, the results suggest that in vivo FDPM data for tomographic 
reconstruction may be obtained using an expanded or planar illumination geometry and 
area detection.  Typically, measurements of FDPM are obtained using a point 
illumination – point detection scheme, where area images are compiled after scanning a 
single detector across a region of interest and building the image point-by-point.  
However, a scanning method utilizing point illumination – point detection is a highly 
inefficient technique to elicit fluorescence from submerged or deeply embedded 
fluorophores and area measurements can provide a great deal more information or 
data.64,118  Current efforts concentrate on the tomographic reconstruction of area 
measurements of FDPM following planar illumination.117
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9. SUMMARY AND CONCLUSIONS
A new optical imaging modality has been developed for in vivo clinical imaging of near-
infrared fluorescence resulting from fluorescent contrast agents specifically targeted to 
molecular markers of carcinoma.  The imaging system is comprised of an intensified 
charge-coupled device (ICCD) for the detection of ultra-low levels of re-emitted 
fluorescence following the delivery of excitation light provided by a laser diode whose 
monochromatic output has been expanded to illuminate an area of the tissue surface.
The ICCD detection system is capable of both continuous wave and frequency-domain 
modes of operation.  Furthermore, the intensified-detection allows for sub-second 
exposure times, permitting the acquisition of dynamic fluorescence imaging immediately 
following administration of the contrast agent.  
The work presented herein also demonstrates the capacity to obtain time-resolved 
measurements, or measurements obtained in the frequency-domain.  In addition to mean 
signal intensity, frequency-domain measurements provide information regarding the 
temporal propagation of fluorescent photon density waves.  While this information may 
not be heeded at the current time given that a plethora of information is available using 
simpler continuous-wave technology, it nonetheless motivates the next step in near-
infrared fluorescence optical imaging.  Continuous wave optical imaging may be well 
suited for small animal imaging studies geared toward the development of novel 
diagnostic imaging agents and therapeutic drugs; however, the future of optical imaging 
for the detection of heterogeneous large volumes necessitates the use of a technology 
capable of deep-tissue imaging.  Thus, the work presented in this dissertation also serves 
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to motivate the development of a frequency-domain fluorescence imaging system for use 
on human subjects.
A summary of the important findings presented in this dissertation include:
1. Frequency-domain photon migration measurements obtained from the surface of 
homogenous turbid media may be used to accurately determine the absorption 
and reduced scattering coefficients characteristic of the media.  The absorption 
and reduced scattering coefficients are determined least accurately when relative 
measurements of average light intensity relDCI  are employed either alone or in a 
combination with relative modulation amplitude data relACI  and/or relative phase 
shift data relθ .  The absorption and reduced scattering coefficients may be found 
accurate to within 15% and 11%, respectively, of the values obtained from 
standard single-pixel measurements when relθ  measurements are employed 
alone or in combination with relACI  data.
2. Unlike dynamic fluorescence images of indocyanine green (ICG), dynamic 
fluorescence images of carotene-conjugated 2-devinyl-2- (1-hexyloxyethyl) 
pyropheophorbide (HPPH-car) may be used discriminate spontaneous canine 
adenocarcinoma from normal mammary tissue. Upon collecting time-dependent 
fluorescence images at the tissue surface overlying both normal and diseased 
tissue volumes immediately following intravenous administration of fluorescent 
contrast agent into the canine, and fitting these images to a pharmacokinetic 
model describing the uptake (wash-in) and release (wash-out) of fluorescent dye, 
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the pharmacokinetics of fluorescent dye may be spatially determined. Mapping 
the fluorescence intensity owing to ICG indicates that the dye acts as a blood 
pool or blood persistent agent, for the model parameters show no difference in 
the ICG uptake rates between normal and diseased tissue regions. In contrast, 
HPPH-car pharmacokinetics illustrated active uptake into diseased tissues, 
perhaps owing to the overexpression of LDL receptors associated with the 
malignant cells.
3. Dynamic fluorescence intensity measurements obtained from a murine Kaposi’s 
sarcoma model immediately following the intravenous injection of an integrin-
targeting cyanine dye conjugate, RGD-Cy5.5 may be used in conjunction with a 
pharmacokinetic model to determine kinetic properties of the conjugate dye.  The 
results indicate that the conjugate dye behaves similarly in normal tissue to the 
free Cy5.5 dye while it possesses increased uptake in tumor tissue.  Furthermore, 
the rate constant governing the cellular uptake of the conjugate dye within the 
Kaposi’s sarcoma tumor tissue was estimated to have a value of 0.16-sec-1.  
Moreover, based on the results one may speculate that the integrin receptor 
turnover occurs approximately every 24-hours.  The findings further suggest that 
if dynamic fluorescence imaging is combined with a suitable pharmacokinetic 
model describing dye distribution throughout the body, it may be possible to 
describe molecular phenomena such as binding specificity, degree of receptor 
expression, and receptor turnover rate.
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4. The specificity of a novel EGF-Cy5.5 fluorescent optical probe for epidermal 
growth factor receptor (EGFr) may be assessed using continuous-wave
fluorescence imaging accomplished via an ICCD camera.  Fluorescence imaging 
performed on mice with MDA-MB-468 cancer, known to overexpress EGFr,
confirms no favorable binding to tumor by the free dyes ICG and Cy5.5.  In 
contrast, EGF-Cy5.5 exhibits selective accumulation in the MDA-MB-468 tumor.  
Moreover, tumor uptake of EGF-Cy5.5 is blocked by pre-injection of anti-EGFr 
antibody C225, further demonstrating specificity of the targeted contrast agent.  
Furthermore, fluorescence due to the EGF-Cy5.5 conjugate dye may be detected 
at the site of the MDA-MB-468 tumor, for a period of up to 192-hrs following 
the administration of the contrast agent.
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APPENDIX A:  DIFFUSION APPROXIMATION TO THE RADIATIVE 
TRANSPORT EQUATION
The propagation of light through an absorbing and scattering medium is described by the 
radiative transport equation (RTE).  Assuming that photons travel at the same speed or 
energy through a homogeneous medium, the RTE describing the accumulation and loss 
of photons within the medium is given by:119
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where ( )ˆ, , tϕ r Ω  represents the angular flux of photons in direction Ω̂  at position r at 
time t; ( )ˆ, ,s tr Ω  represents the photon source in direction Ω̂  at position r at time t; c is 
the speed of light within the medium, and; ( )ˆ ˆp ′ →Ω Ω  is the probability that scattering 
events carry photons from ˆ ′Ω  into Ω̂ .  Integrating Eq. (B.1) over all solid angles yields:
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where ( ), tΦ r , ( ), tJ r , and ( ),S tr  are the angle-independent fluence rate, current 
density, and angle-independent photon source, respectively, and are represented by:
( ) ( )
4
ˆ ˆ, , ,t t d
π
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Eq. (A.2) contains two dependent variables, namely, the fluence rate, ( )t,rΦ , and the 
current density, ( )t,rJ .  As a result, a second expression for ( )t,rJ  is required.  To 
obtain this second expression, the angular photon flux is first approximated as the sum of 
an isotropic fluence rate and a directional flux:
( ) ( ) ( )1 3ˆ ˆ, , , ,4 4t t tϕ π π≅ Φ + ⋅r r J rΩ Ω . (A.6)
The assumption is equivalent to saying that photons are multiply scattered before being 
absorbed or detected, which holds true when s aµ µ>> .  This expression for the angular 
photon flux, Eq. (A.6), is next substituted into Eq. (A.1), and the resulting expression is 
multiplied by Ω̂  and integrated over all solid angles to yield:
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where g is the average cosine of the scattering angle, and 
( ) ( )1
4
ˆ ˆ ˆ, , ,S t s t d
π
= Ω Ω∫r r Ω . (A.8)
Further, Eq. (A.7) can be reduced by assuming that the photon source is isotropic, and 
the time rate of change in current density is much slower than the collision frequency.  
Mathematically, these assumptions are stated as:
( ) ( ) 1ˆ, , , 0s t s t S≅ ⇒ =r rΩ , (A.9)
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and as a result, Eq. (A.7) simplifies to the following form of Fick’s Law:










( )1s sgµ µ′ = − . (A.13)
D is the optical diffusion coefficient and sµ′  is known as the isotropic scattering 
coefficient.  Finally, inserting Eq. (A.11) into Eq. (A.2) yields the time-domain diffusion
equation of radiative transfer:119
( ) ( ) ( ) ( )2,1 , , ,a
t
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A Fourier transfer of Eq. (A.14) yields the frequency-domain diffusion equation of 
radiative transfer:
( ) ( ) ( ) ( )2 ˆˆ ˆ ˆ, , , ,a
i D S
c
ω ω ω µ ω ωΦ − ∇ Φ + Φ =r r r r (A.15)
where ( )ˆ ,ωΦ r  is the complex AC fluence at position r and angular frequency ω and 
can be expressed as:
( ) ( )ACˆ , I exp iω θΦ = −r (A.16)
where IAC and θ represent the AC amplitude and phase lag relative to the source, 
respectively.
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APPENDIX B:  LAPLACE TRANSFORM SOLUTION TO THE COUPLED 
DIFFERENTIAL EQUATIONS OF THE THREE-COMPARTMENT 
PHARMACOKINETIC MODEL
The Laplace transform ( )g s  of a function ( )f t  is defined as 
( ) ( ) ( )
0
expg s st f t dt
∞
= −∫ (B.1)
where s  is a complex variable and the function ( )f t  is referred to as the inverse 
Laplace transform of ( )g s .  The Laplace transform and its inverse may be expressed in 
shorthand by use of the Laplace operator L  as 
( ) ( )g s f t =  L , (B.2)
( ) ( )1f t g s−  =  -L . (B.3)
Table B.1 provides the Laplace transform, and hence the inverse transform, of functions 
frequently encountered in the solution of the coupled, ordinary, linear differential 
equations that arise in the study of pharmacokinetics.  In particular, the table of Laplace 
transforms is valuable in solving the differential equations that arise in the three-
compartment pharmacokinetic model developed in Section 6.2.  
The time- dependent concentration of contrast agent in each of the three 
compartments – the blood, extravascular, extracellular space, and the cellular 
compartment (see Section 6.2), following intravenous bolus administration may be 
expressed as a set of three coupled, ordinary, linear differential equations given in 
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Table B.1.  Table of Laplace transforms.120
, ,α β γ  are constants (rate constants)
s  is the Laplace complex variable
x  is a time-dependent variable (concentration)
x  is the Laplace transform of a time-dependent variable
ox  is the initial condition, i.e. the value of x  at 0t =
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Section 6.2 by Eqs. (6.3), (6.4), and (6.5).  Performing the Laplace transform on the 
differential equations and applying the appropriate initial conditions results in the 
following expressions:
B Bo B B r EESsC C k C k C− = − + , (B.4)
EES EES EES p BsC k C k C= − + , (B.5)
c c EESsC k C= − . (B.6)
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Upon algebraic manipulation, Eqs. (B.4 – B.6) may be rewritten with only the Laplace-
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Performing the inverse Laplace transform on Eqs. (B.7), (B.8) and (B.9) using the 
appropriate relationships provided in Table B.1 facilitates the straightforward solution to 
the system of differential equations.  Thus, the time-dependent concentration of dye in 
each of the three-compartments may be expressed as:










( ) ( ) ( ) ( )[ ]tktkCC EESEESBoB ββααβα −−−−−−= expexp , (B.13)
















Furthermore, the observed time-dependent fluorescent intensity may be expressed as a 
weighted sum of the concentration of dye in each compartment
( ) CEESB CwCwCwtI 321 ++≅ . (B.15)
Combining Eqs. (B.12), (B.13), (B.14), and (B.15) enables the time-dependent 
fluorescent intensity to be written in the form of a double-exponential, five-parameter 
expression
( ) ( )[ ] ( )[ ]tBtAItI o βα −−+−−+= exp1exp1 , (B.16)
where the parameters are given by
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and α and β are complex rate constants previously defined by Eqs. (B.10) and (B.11).
Finally, as discussed in Section 6.2, Eq. (B.16) may be further simplified to a four-
parameter expression by employing a background subtraction technique, the
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